Safety and immunogenicity of an rAd26 and rAd5 vecto COVID-19 vaccine in two formulations: two open, non-r Russia

Lancet, The

396, 887-897

DOI: 10.1016/s0140-6736(20)31866-3

Citation Report

#	Article	IF	Citations
1	Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control. British Journal of Biomedical Science, 2020, 77, 168-184.	1.3	12
2	A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy, 2020, 5, 237.	17.1	427
3	SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet, The, 2020, 396, 1595-1606.	13.7	511
4	SARS-CoV-2 vaccines in development. Nature, 2020, 586, 516-527.	27.8	1,659
6	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, The, 2020, 396, 1979-1993.	13.7	1,196
7	Detection, Mapping, and Proteotyping of SARS-CoV-2 Coronavirus with High Resolution Mass Spectrometry. ACS Infectious Diseases, 2020, 6, 3269-3276.	3.8	34
8	The immunology of SARS-CoV-2 infections and vaccines. Seminars in Immunology, 2020, 50, 101422.	5.6	85
9	Leadership in a time of crisis: Lessons learned from a pandemic. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2021, 35, 405-414.	4.0	23
10	Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19. Viruses, 2020, 12, 1324.	3.3	35
12	SARS coronavirus 2: from genome to infectome. Respiratory Research, 2020, 21, 318.	3.6	62
13	Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens International symposium. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 723-730.	1.4	22
14	Vaccines against COVID-19. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 703-705.	1.4	31
15	An update on the global vaccine development for coronavirus. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 2053-2055.	3.6	20
16	COVID-19 vaccines: early success and remaining challenges. Lancet, The, 2020, 396, 868-869.	13.7	29
17	Safety and efficacy of the Russian COVID-19 vaccine: more information needed â€“ Authorsâ€™ reply. Lancet, The, 2020, 396, e54-e55.	13.7	25
18	Safety and efficacy of the Russian COVID-19 vaccine: more information needed. Lancet, The, 2020, 396, e53.	13.7	27
19	Donâ€™t shortchange public trust in science. Nature Cancer, 2020, 1, 855-856.	13.2	0
20	Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic Strategies. International Journal of Molecular Sciences, 2020, 21, 6790.	4.1	52

#	Article	IF	Citations
21	Vaccines for COVID-19. Clinical and Experimental Immunology, 2020, 202, 162-192.	2.6	185
22	Seven days in medicine: 2-8 September 2020. BMJ, The, 2020, 370, m3486.	6.0	0
23	Coronavirus vaccine development: from SARS and MERS to COVID-19. Journal of Biomedical Science, 2020, 27, 104.	7.0	287
24	Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). Frontiers in Immunology, 2020, 11, 571481.	4.8	48
25	COVID-19: Coronavirus Vaccine Development Updates. Frontiers in Immunology, 2020, 11, 602256.	4.8	143
26	Navigating the Quagmire: Comparison and Interpretation of COVID-19 Vaccine Phase 1/2 Clinical Trials. Vaccines, 2020, 8, 746.	4.4	6
27	Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Science Immunology, 2020, 5, .	11.9	244
28	Current Prevention of COVID-19: Natural Products and Herbal Medicine. Frontiers in Pharmacology, 2020, 11, 588508.	3.5	99
29	In Pursuit of a SARS-CoV-2 Vaccine. Journal of Foot and Ankle Surgery, 2020, 59, 1133-1134.	1.0	1
30	The roles of nausea and vomiting in COVID-19: did we miss something?. Journal of Microbiology, Immunology and Infection, 2021, 54, 541-546.	3.1	20
31	COVID-19 lockdown: animal life, ecosystem and atmospheric environment. Environment, Development and Sustainability, 2021, 23, 8161-8178.	5.0	50
32	A promising inactivated whole-virion SARS-CoV-2 vaccine. Lancet Infectious Diseases, The, 2021, 21, 2-3.	9.1	15
33	Learning from the past: development of safe and effective COVID-19 vaccines. Nature Reviews Microbiology, 2021, 19, 211-219.	28.6	126
34	T cell immunity to SARS-CoV-2 following natural infection and vaccination. Biochemical and Biophysical Research Communications, 2021, 538, 211-217.	2.1	88
35	Racing to immunity: Journey to a COVIDâ€19 vaccine and lessons for the future. British Journal of Clinical Pharmacology, 2021, 87, 3408-3424.	2.4	16
36	Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward. Human Vaccines and Immunotherapeutics, 2021, 17, 1635-1649.	3.3	14
37	SARS-CoV-2: Targeted managements and vaccine development. Cytokine and Growth Factor Reviews, 2021, 58, 16-29.	7.2	44
38	Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. Biomedicine and Pharmacotherapy, 2021, 133, 111008.	5.6	40

#	Article	IF	Citations
39	COVID-19: A review of therapeutic strategies and vaccine candidates. Clinical Immunology, 2021, 222, 108634.	3.2	180
40	Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak. SLAS Discovery, 2021, 26, 311-329.	2.7	4
41	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nature Medicine, 2021, 27, 279-288.	30.7	265
42	Viral targets for vaccines against COVID-19. Nature Reviews Immunology, 2021, 21, 73-82.	22.7	832
43	The management of hematologic malignancies during the COVID-19 pandemic. Expert Opinion on Pharmacotherapy, 2021, 22, 565-582.	1.8	9
44	SARSâ€CoVâ€2 candidate vaccines â€•composition, mechanisms of action and stages of clinical development. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1922-1924.	5.7	23
46	COVID-19. Critical Care Nursing Quarterly, 2021, 44, 128-137.	0.8	17
47	An update on coronavirus disease-19 vaccines. Journal of Medical Evidence, 2021, 2, 24.	0.1	2
48	Isolating SARS-CoV-2 Strains From Countries in the Same Meridian: Genome Evolutionary Analysis. JMIR Bioinformatics and Biotechnology, 2021, 2, e25995.	0.9	6
49	A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques. Emerging Microbes and Infections, 2021, 10, 342-355.	6.5	37
50	Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerging Microbes and Infections, 2021, 10, 629-637.	6.5	118
51	Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine. Emerging Microbes and Infections, 2021, 10, 1598-1608.	6.5	76
52	Older adults: panoramic view on the COVID-19 vaccination. AIMS Public Health, 2021, 8, 388-415.	2.6	14
55	Pandemic Viruses at Hajj: Influenza and COVID-19. , 2021, , 1-19.		0
56	Meteorological parameters and COVID-19 spread-Russia a case study. , 2021, , 179-190.		2
57	Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study. Brain Communications, 2021, 3, fcab169.	3.3	48
58	COVID-19: Characteristics and Therapeutics. Cells, 2021, 10, 206.	4.1	177
59	Gamma irradiation-mediated inactivation of enveloped viruses with conservation of genome integrity: Potential application for SARS-CoV-2 inactivated vaccine development. Open Life Sciences, 2021, 16, 558-570.	1.4	8

#	Article	IF	Citations
60	The effects of the Russian vaccine (Sputnik V) on the volunteers. Apollo Medicine, 2021, .	0.0	0
61	Pandemic Viruses at Hajj: Influenza and COVID-19. , 2021, , 1249-1266.		0
62	An update to â€œnovel therapeutic approaches for treatment of COVID-19â€• Journal of Molecular Medicine, 2021, 99, 303-310.	3.9	22
63	A COVID-19 Vaccine: Big Strides Come with Big Challenges. Vaccines, 2021, 9, 39.	4.4	78
64	COVID-19 vaccination and allergen immunotherapy (AIT) - A position paper of the German Society for Applied Allergology (AeDA) and the German Society for Allergology and Clinical Immunology (DGAKI). Allergologie Select, 2021, 5, 251-259.	3.1	9
65	An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110214.	1.7	29
66	Coronavirus disease 2019 vaccines and relevant adverse reactions. Allergy Asthma & Respiratory Disease, 2021, 9, 124.	0.2	3
67	Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. Frontiers in Physiology, 2021, 12, 593223.	2.8	113
70	Ten principles for generating accessible and useable COVIDâ€19 environmental science and a fitâ€forâ€purpose evidence base. Ecological Solutions and Evidence, 2021, 2, e12041.	2.0	8
71	The Worldwide Effort to Develop Vaccines for COVID-19. Advances in Experimental Medicine and Biology, 2021, 1327, 215-223.	1.6	3
72	Long-Term Analysis of Antibodies Elicited by Sputnik V in Tucuman, Argentina. SSRN Electronic Journal, 0, , .	0.4	1
73	Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19). 3 Biotech, 2021, 11, 89.	2.2	29
74	Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019. Advanced NanoBiomed Research, 2021, 1, 2000063.	3.6	5
75	The 2020 race towards SARS-CoV-2 specific vaccines. Theranostics, 2021, 11, 1690-1702.	10.0	71
76	Anti-science kills: From Soviet embrace of pseudoscience to accelerated attacks on US biomedicine. PLoS Biology, 2021, 19, e3001068.	5.6	42
78	Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. Comparative Medicine, 2021, 71, 342-358.	1.0	3
79	A peptide-based subunit candidate vaccine against SARS-CoV-2 delivered by biodegradable mesoporous silica nanoparticles induced high humoral and cellular immunity in mice. Biomaterials Science, 2021, 9, 7287-7296.	5.4	10
80	SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines. Vaccines, 2021, 9, 36.	4.4	41

#	Article	IF	Citations
81	SARS-CoV-2: vaccines in the pandemic era. Military Medical Research, 2021, 8, 1.	3.4	104
82	Flattening the Curve of COVID-19 Vaccine Rejectionâ€"An International Overview. Vaccines, 2021, 9, 44.	4.4	107
83	The hamletic dilemma of patients waiting for kidney transplantation during the COVIDâ€19 pandemic: To accept or not to accept (an organ offer)?. Transplant Infectious Disease, 2021, 23, e13560.	1.7	9
85	Vaccines for COVID-19 - state of the art. Revista Brasileira De Saude Materno Infantil, 2021, 21, 13-19.	0.5	22
86	COVID-19 vaccines: implementation, limitations and opportunities. Global Health & Medicine, 2021, 3, 1-5.	1.4	28
87	Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases. RMD Open, 2021, 7, e001594.	3.8	59
88	Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet, The, 2021, 397, 642-643.	13.7	252
89	Integrated vaccination and physical distancing interventions to prevent future COVID-19 waves in Chinese cities. Nature Human Behaviour, 2021, 5, 695-705.	12.0	111
90	Expert Opinions on the Most Promising Treatments and Vaccine Candidates for COVID-19: Global Cross-sectional Survey of Virus Researchers in the Early Months of the Pandemic. JMIR Public Health and Surveillance, 2021, 7, e22483.	2.6	2
92	Adoptive Immunotherapy beyond CAR T-Cells. Cancers, 2021, 13, 743.	3.7	57
93	Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments. Annual Review of Pharmacology and Toxicology, 2022, 62, 25-53.	9.4	20
94	SARS-CoV-2 Vaccination for Childrenâ€"An Open Issue. Pediatric Reports, 2021, 13, 95-97.	1.3	3
96	Winter Is Coming! Clinical, Immunologic, and Practical Considerations for Vaccinating Patients With Inflammatory Bowel Disease During the Coronavirus Disease-2019 Pandemic. Gastroenterology, 2021, 160, 639-644.	1.3	12
97	Codon Usage and Adenovirus Fitness: Implications for Vaccine Development. Frontiers in Microbiology, 2021, 12, 633946.	3.5	10
98	Hyperglycemia at admission is a strong predictor of mortality and severe/critical complications in COVID-19 patients: a meta-analysis. Bioscience Reports, 2021, 41, .	2.4	32
99	COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. Journal of Hematology and Oncology, 2021, 14, 38.	17.0	87
102	A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. Frontiers in Immunology, 2021, 12, 631139.	4.8	117
103	Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors. International Journal of Molecular Sciences, 2021, 22, 2417.	4.1	17

#	Article	IF	Citations
104	Viral Vectors for COVID-19 Vaccine Development. Viruses, 2021, 13, 317.	3.3	65
105	COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform. Vaccines, 2021, 9, 171.	4.4	43
106	Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet, The, 2021, 397, 671-681.	13.7	1,339
107	Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need. Signal Transduction and Targeted Therapy, 2021, 6, 48.	17.1	79
108	Development and deployment of COVID-19 vaccines for those most vulnerable. Science Translational Medicine, 2021, 13, .	12.4	60
109	SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. Npj Vaccines, 2021, 6, 28.	6.0	507
110	SARS-CoV-2 virus: Vaccines in development. Fundamental Research, 2021, 1, 131-138.	3.3	12
111	Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19. International Journal of Infectious Diseases, 2021, 104, 441-451.	3.3	14
112	Potential COVIDâ€19 Therapeutic Agents and Vaccines: An Evidenceâ€Based Review. Journal of Clinical Pharmacology, 2021, 61, 429-460.	2.0	22
113	Does COVID-19 Vaccination Warrant the Classical Principle â€œofelein i mi vlaptinâ€?. Medicina (Lithuania), 2021, 57, 253.	2.0	10
114	Adverse Events Reported From ÂCOVID-19 Vaccine Trials: A Systematic Review. Indian Journal of Clinical Biochemistry, 2021, 36, 427-439.	1.9	175
115	The conundrum of current anti-SARS-CoV-2 vaccines. Cytokine and Growth Factor Reviews, 2021, 60, 46-51.	7.2	6
118	The potential neurological effect of the COVIDâ€19 vaccines: A review. Acta Neurologica Scandinavica, 2021, 144, 3-12.	2.1	85
119	An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery. Pharmaceutics, 2021, 13, 455.	4.5	55
120	Development of COVID-19 vaccines utilizing gene therapy technology. International Immunology, 2021, 33, 521-527.	4.0	19
122	COVID-19 vaccines: rapid development, implications, challenges and future prospects. Human Cell, 2021, 34, 711-733.	2.7	227
123	Immunity to SARS-CoV-2: Lessons Learned. Frontiers in Immunology, 2021, 12, 654165.	4.8	33
125	SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines. Vaccines, 2021, 9, 227.	4.4	47

#	Article	IF	Citations
126	Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective. Viruses, 2021, 13, 418.	3.3	51
127	Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations. Vaccines, 2021, 9, 221.	4.4	132
128	COVID-19 in early 2021: current status and looking forward. Signal Transduction and Targeted Therapy, 2021, 6, 114.	17.1	191
129	COVID-19 Reinfection in the Face of a Detectable Antibody Titer. Cureus, 2021, 13, e14033.	0.5	4
130	Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2. Npj Vaccines, 2021, 6, 37.	6.0	14
131	Impact of pathogen reduction methods on immunological properties of the COVIDâ€19 convalescent plasma. Vox Sanguinis, 2021, 116, 665-672.	1.5	13
132	Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines. Diagnostics, 2021, 11, 579.	2.6	114
133	Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing. Viruses, 2021, 13, 532.	3.3	18
134	Current progress and challenges in the design and development of a successful COVID-19 vaccine. Fundamental Research, 2021, 1, 139-150.	3.3	19
135	Features of developing SARS-CoV-2 nucleocapsid protein population-based seroprevalence during the first wave of the COVID-19 epidemic in the Russian Federation. Russian Journal of Infection and Immunity, 2021, 11, 297-323.	0.7	30
136	SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription. Genome Medicine, 2021, 13, 43.	8.2	44
137	Frontrunners in the race to develop a SARS-CoV-2 vaccine. Canadian Journal of Microbiology, 2021, 67, 189-212.	1.7	11
139	Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks. Stem Cell Reports, 2021, 16, 398-411.	4.8	18
140	Novel approaches for vaccine development. Cell, 2021, 184, 1589-1603.	28.9	145
141	Covid-19: What do we know about Sputnik V and other Russian vaccines?. BMJ, The, 2021, 372, n743.	6.0	51
142	Risk management strategies and therapeutic modalities to tackle COVID-19/SARS-CoV-2. Journal of Infection and Public Health, 2021, 14, 331-346.	4.1	12
143	Profiles of current COVID-19 vaccines. Wiener Klinische Wochenschrift, 2021, 133, 271-283.	1.9	32
144	Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19. Vaccines, 2021, 9, 296.	4.4	6

#	Article	IF	Citations
145	COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nature Reviews Clinical Oncology, 2021, 18, 313-319.	27.6	103
146	Advances in gene-based vaccine platforms to address the COVID-19 pandemic. Advanced Drug Delivery Reviews, 2021, 170, 113-141.	13.7	71
147	TREATMENT MODALITIES OF THE COVID-19 PANDEMIC THROUGH REPURPOSED DRUGS AND STATUS OF VACCINES. International Journal of Applied Pharmaceutics, 0, , 48-58.	0.3	4
148	Knowing and combating the enemy: a brief review on SARS-CoV-2 and computational approaches applied to the discovery of drug candidates. Bioscience Reports, 2021, 41, .	2.4	16
149	COVID-19: Insights into Potential Vaccines. Microorganisms, 2021, 9, 605.	3.6	31
150	Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans. Science Advances, 2021, 7, .	10.3	100
151	SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study. British Journal of Surgery, 2021, 108, 1056-1063.	0.3	321
153	Genome-Editing Technologies in Biomedical Research: The Regulatory Conditions for the Development. Kutafin University Law Review, 2021, 8, 115-128.	0.1	0
156	COVID-19 vaccines: Global challenges and prospects forum recommendations. International Journal of Infectious Diseases, 2021, 105, 448-451.	3.3	7
157	The COVID-19 Vaccines: Recent Development, Challenges and Prospects. Vaccines, 2021, 9, 349.	4.4	60
159	The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland. Vaccines, 2021, 9, 382.	4.4	90
160	COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials. Pharmaceuticals, 2021, 14, 406.	3.8	101
161	Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 1535.	7.4	260
162	A stable platform for the production of virus-like particles pseudotyped with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein. Virus Research, 2021, 295, 198305.	2.2	14
163	An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times. Vaccines, 2021, 9, 433.	4.4	85
164	Nanocarrier vaccines for SARS-CoV-2. Advanced Drug Delivery Reviews, 2021, 171, 215-239.	13.7	66
165	Covid-19 AÅŸÄ±larÄ±. SÃ¼leyman Demirel Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 0, , .	0.2	2
166	Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials. Chinese Medical Journal, 2021, 134, 1289-1298.	2.3	49

#	Article	IF	Citations
167	Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model. MBio, 2021, 12, .	4.1	62
168	Strategies for Immunomonitoring after Vaccination and during Infection. Vaccines, 2021, 9, 365.	4.4	12
170	Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration. AAPS PharmSciTech, 2021, 22, 126.	3.3	41
171	Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases. Npj Vaccines, 2021, 6, 60.	6.0	154
172	Vaccines Developed against COVID-19: a narrative review. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2021, 67, 625-631.	0.7	0
174	Vaccines for a healthy future: 21st DCVMN Annual General Meeting 2020 report. Vaccine, 2021, 39, 2479-2488.	3.8	4
175	Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19. Frontiers in Molecular Biosciences, 2021, 8, 635337.	3.5	22
176	Na+/K+-ATPase as a Target of Cardiac Glycosides for the Treatment of SARS-CoV-2 Infection. Frontiers in Pharmacology, 2021, 12, 624704.	3.5	17
177	COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations. Frontiers in Immunology, 2021, 12, 669339.	4.8	81
178	Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines. Immunological Investigations, 2021, 50, 743-779.	2.0	16
180	Polymer-based nano-therapies to combat COVID-19 related respiratory injury: progress, prospects, and challenges. Journal of Biomaterials Science, Polymer Edition, 2021, 32, 1219-1249.	3.5	19
181	Effect of an Adenovirus-Vectored Universal Influenza Virus Vaccine on Pulmonary Pathophysiology in a Mouse Model. Journal of Virology, 2021, 95, .	3.4	7
182	The COVID-19 Vaccine in Clinical Trials: Where Are We Now?. Infectious Diseases & Immunity, 2021, 1, 43-51.	0.6	4
183	Status Report on COVID-19 Vaccines Development. Current Infectious Disease Reports, 2021, 23, 9.	3.0	56
184	The importance of genomic analysis in cracking the coronavirus pandemic. Expert Review of Molecular Diagnostics, 2021, 21, 547-562.	3.1	14
185	Progress in research on the S protein as the target of COVID-19 vaccines. Expert Review of Vaccines, 2021, 20, 769-772.	4.4	6
186	Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes. Public Health, 2021, 193, 57-60.	2.9	10
187	Coronavirus Disease 2019: An Overview of the Complications and Management. , 0, , 1-28.		1

#	Article	IF	Citations
189	Influenza Virus and SARS-CoV-2 Vaccines. Journal of Immunology, 2021, 206, 2509-2520.	0.8	11
190	Immune response induced by oral administration with a Saccharomyces cerevisiae-based SARS-CoV-2 vaccine in mice. Microbial Cell Factories, 2021, 20, 95.	4.0	23
191	Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial. Lancet, The, 2021, 397, 1881-1883.	13.7	26
192	Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates. Emerging Microbes and Infections, 2021, 10, 1002-1015.	6.5	22
194	Silencing of SARSâ€CoVâ€2 with modified siRNAâ€peptide dendrimer formulation. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2840-2854.	5.7	65
196	Coronavirus disease 2019 (COVIDâ€19) vaccines: A concise review. Oral Diseases, 2022, 28, 2326-2336.	3.0	36
197	Mild Adverse Events of Sputnik V Vaccine in Russia: Social Media Content Analysis of Telegram via Deep Learning. Journal of Medical Internet Research, 2021, 23, e30529.	4.3	27
198	Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV-2 Infection. Current Medicinal Chemistry, 2022, 29, 4-18.	2.4	49
199	High-throughput sequencing in vaccine research. Journal of Veterinary Research (Poland), 2021, 65, 131-137.	1.0	1
201	COVIDâ€19: vaccineâ€™s progress. Microbial Biotechnology, 2021, 14, 1246-1257.	4.2	16
202	SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?. Advanced Drug Delivery Reviews, 2021, 172, 314-338.	13.7	75
203	siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses. Molecular Pharmaceutics, 2021, 18, 2105-2121.	4.6	34
204	COVID-19 Vaccines Based on Adenovirus Vectors. Trends in Biochemical Sciences, 2021, 46, 429-430.	7.5	24
205	Management of immune thrombocytopenia during COVID-19 pandemic. Gematologiya I Transfuziologiya, 2021, 66, 20-36.	0.6	1
207	A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques. Vaccines, 2021, 9, 520.	4.4	28
208	2019 Coronavirus disease (COVID-19): contribution of rheumatology. Terapevticheskii Arkhiv, 2021, 93, .	0.8	6
209	Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial â€“ Authors' reply. Lancet, The, 2021, 397, 1883-1884.	13.7	17
210	Covid-19: Sputnik vaccine rockets, thanks to Lancet boost. BMJ, The, 2021, 373, n1108.	6.0	15

#	Article	IF	Citations
211	Cutaneous adverse effects of the available COVID-19 vaccines. Clinics in Dermatology, 2021, 39, 523-531.	1.6	69
212	Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. Npj Vaccines, 2021, 6, 74.	6.0	198
214	Simultaneous Evaluation of a Vaccine Component Microheterogeneity and Conformational Integrity Using Native Mass Spectrometry and Limited Charge Reduction. Journal of the American Society for Mass Spectrometry, 2021, 32, 1631-1637.	2.8	8
215	On the road to ending the COVID-19 pandemic: Are we there yet?. Virology, 2021, 557, 70-85.	2.4	38
216	COVID-19 vaccine decisions: considering the choices and opportunities. Microbes and Infection, 2021, 23, 104811.	1.9	17
217	Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Vaccines, 2021, 9, 467.	4.4	228
218	Understanding Post Entry Sorting of Adenovirus Capsids; A Chance to Change Vaccine Vector Properties. Viruses, 2021, 13, 1221.	3.3	9
219	Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans. Vaccines, 2021, 9, 588.	4.4	12
220	Type-2 Diabetes as a Risk Factor for Severe COVID-19 Infection. Microorganisms, 2021, 9, 1211.	3.6	38
222	COVID-19 vaccines: Frequently asked questions and updated answers. Infectious Diseases Now, 2021, 51, 319-333.	1.6	10
223	Levels of Produced Antibodies after Vaccination with mRNA Vaccine; Effect of Previous Infection with SARS-CoV-2. Journal of Clinical Medicine, 2021, 10, 2842.	2.4	7
224	Key Considerations for the Development of Safe and Effective SARSâ€CoVâ€2 Subunit Vaccine: A Peptideâ€Based Vaccine Alternative. Advanced Science, 2021, 8, e2100985.	11.2	16
225	The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2). BioMed Research International, 2021, 2021, 1-20.	1.9	13
226	Naturally Occurring Bioactives as Antivirals: Emphasis on Coronavirus Infection. Frontiers in Pharmacology, 2021, 12, 575877.	3.5	18
227	COVIDâ€19 in gastroenterology: Where are we now? Current evidence on the impact of COVIDâ€19 in gastroenterology. United European Gastroenterology Journal, 2021, 9, 750-765.	3.8	18
228	COVID-19 Infection and Circulating Microparticlesâ€"Reviewing Evidence as Microthrombogenic Risk Factor for Cerebral Small Vessel Disease. Molecular Neurobiology, 2021, 58, 4188-4215.	4.0	16
229	The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3546-3567.	3.8	152
231	Immunological Approaches to the Treatment of Novel Coronavirus Infection (Review). Sovremennye Tehnologii V Medicine, 2021, 13, 81.	1.1	4

#	Article	IF	Citations
232	Coronavirus disease 2019 vaccination in transplant recipients. Current Opinion in Infectious Diseases, 2021, 34, 275-287.	3.1	15
233	Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?. International Journal of Pharmaceutics, 2021, 603, 120686.	5.2	83
234	Gam-COVID-Vac (Sputnik V): a heterologous adenoviral vector-based COVID-19 vaccine. Aging Pathobiology and Therapeutics, 2021, 3, 43-45.	0.5	1
235	What gastroenterologists should know about SARSâ€"CoV 2 vaccine: World Endoscopy Organization perspective. United European Gastroenterology Journal, 2021, 9, 787-796.	3.8	4
237	Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome. Cells, 2021, 10, 1412.	4.1	6
240	History and Global Status of the New Coronavirus Covid-2019 and Aspects of Previous Infections of SARS-CoV and MERS-CoV: A Systematic Review. Coronaviruses, 2021, 2, .	0.3	0
241	SARSâ€CoVâ€2 and hypertension. Physiological Reports, 2021, 9, e14800.	1.7	11
242	A rational strategy to support approved COVID-19 vaccines prioritization. Human Vaccines and Immunotherapeutics, 2021, 17, 3474-3477.	3.3	4
244	Adaptation of the MTT assay for detection of neutralizing antibodies against the SARS-CoV-2 virus. Zhurnal Mikrobiologii Epidemiologii I Immunobiologii, 2021, 98, 253-265.	1.0	10
246	Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia. Nauchno-Prakticheskaya Revmatologiya, 2021, 59, 239-254.	1.0	40
247	Current vaccine technology with an emphasis on recombinant measles virus as a new perspective for vaccination against SARS-CoV-2. Euro-Mediterranean Journal for Environmental Integration, 2021, 6, 61.	1.3	0
248	Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein. Journal of Medicinal Chemistry, 2022, 65, 2836-2847.	6.4	22
249	Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Medicine, 2021, 19, 173.	5.5	156
250	COVID-19 vaccines: concerns beyond protective efficacy and safety. Expert Review of Vaccines, 2021, 20, 1013-1025.	4.4	56
251	Recent updates on immunological, pharmacological, and alternative approaches to combat COVID-19. Inflammopharmacology, 2021, 29, 1331-1346.	3.9	7
252	Antiviral Activity of Benzydamine Hydrochloride against SARS-CoV-2 in vitro Model. Epidemiologiya I Vaktsinoprofilaktika, 2021, 20, 83-90.	0.8	1
253	A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics. Current Medical Science, 2021, 41, 1037-1051.	1.8	136
254	A â€˜mix and matchâ€™ approach to SARS-CoV-2 vaccination. Nature Medicine, 2021, 27, 1510-1511.	30.7	45

#	Article	IF	Citations
255	Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity. Cells, 2021, 10, 1756.	4.1	19
256	Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC:) Tj ETQq1 1 0.784314 rgBT /Overlock	4.4	94
257	Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. Expert Review of Anti-Infective Therapy, 2021, 19, 1219-1244.	4.4	6
258	Current Perspectives in the Discovery of Newer Medications Against the Outbreak of COVID-19. Frontiers in Molecular Biosciences, 2021, 8, 648232.	3.5	1
259	SARSâ€CoVâ€2 vaccination in patients with inflammatory bowel disease. GastroHep, 2021, 3, 212-228.	0.6	7
260	Human Coronaviruses: Counteracting the Damage by Storm. Viruses, 2021, 13, 1457.	3.3	5
261	Genetic and Chemical Capsid Modifications of Adenovirus Vectors to Modulate Vectorâ€"Host Interactions. Viruses, 2021, 13, 1300.	3.3	9
262	Influence of HLA Class II Polymorphism on Predicted Cellular Immunity Against SARS-CoV-2 at the Population and Individual Level. Frontiers in Immunology, 2021, 12, 669357.	4.8	7
263	An Appraisal of the Current Scenario in Vaccine Research for COVID-19. Viruses, 2021, 13, 1397.	3.3	6
264	A Novel Vaccine Selection Decision-Making Model (VSDMM) for COVID-19. Vaccines, 2021, 9, 718.	4.4	18
265	Indiaâ€™s pragmatic vaccination strategy against COVID-19: a mathematical modelling-based analysis. BMJ Open, 2021, 11, e048874.	1.9	15
267	Modification of the Spike Protein for Vaccines against Enveloped RNA Viruses. Molecular Biology, 2021, 55, 538-547.	1.3	2
268	Mounting evidence suggests Sputnik COVID vaccine is safe and effective. Nature, 2021, 595, 339-340.	27.8	57
269	Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Science Translational Medicine, 2021, 13, .	12.4	56
270	Virus Induced Lymphocytes (VIL) as a novel viral antigen-specific T cell therapy for COVID-19 and potential future pandemics. Scientific Reports, 2021, 11, 15295.	3.3	5
271	Are We Paving the Way to Dig Out of the â€œPandemic Holeâ€? A Narrative Review on SARS-CoV-2 Vaccination: From Animal Models to Human Immunization. Medical Sciences (Basel, Switzerland), 2021, 9, 53.	2.9	1
272	Cancer Cell-specific Transfection of hCas9 Gene Using Ad5F35 Vector. Anticancer Research, 2021, 41, 3731-3740.	1.1	3
273	COVID-19 Pathogenesis: From Molecular Pathway to Vaccine Administration. Biomedicines, 2021, 9, 903.	3.2	5

#	Article	IF	Citations
274	An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. International Immunopharmacology, 2021, 96, 107763.	3.8	35
276	Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Nature Communications, 2021, 12, 4598.	12.8	88
277	Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study. Pain and Therapy, 2021, 10, 1309-1330.	3.2	28
278	Negative results of humoral immunity after anti-SARS-CoV-2 vaccination in patient with advanced ovarian cancer treated with maintenance immunotherapy and targeted therapy: a clinical case and Ð° literature review. Malignant Tumours, 2021, 11, 5-8.	0.5	0
279	Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nature Reviews Immunology, 2021, 21, 475-484.	22.7	434
280	Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. Npj Vaccines, 2021, 6, 104.	6.0	241
281	Nervous and Muscular Adverse Events after COVID-19 Vaccination: A Systematic Review and Meta-Analysis of Clinical Trials. Vaccines, 2021, 9, 939.	4.4	25
283	Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. Npj Vaccines, 2021, 6, 97.	6.0	175
284	Opinion: A serious issue with the standardization of the adenovirus-based COVID-19 vaccines?. Archives of Toxicology, 2021, 95, 3137-3139.	4.2	0
285	Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination. Vaccines, 2021, 9, 910.	4.4	50
286	Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infectious Diseases, The, 2021, 21, 1107-1119.	9.1	345
288	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial. EClinicalMedicine, 2021, 38, 101010.	7.1	28
289	The challenge of structural heterogeneity in the native mass spectrometry studies of the SARS-CoV-2 spike protein interactions with its host cell-surface receptor. Analytical and Bioanalytical Chemistry, 2021, 413, 7205-7214.	3.7	9
290	COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: Indiaâ€™s Role at the WTO Platform. BioMed Research International, 2021, 2021, 1-8.	1.9	33
291	Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity, 2021, 54, 1636-1651.	14.3	165
292	COVID-19 Vaccines in Patients with Maintenance Hemodialysis. Journal of Personalized Medicine, 2021, 11, 789.	2.5	14
293	Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose. Cell Reports Medicine, 2021, 2, 100359.	6.5	62
294	SARS-CoV-2 vaccines â€" the biggest medical research project of the 21st century. Current Opinion in Virology, 2021, 49, 52-57.	5.4	12

#	Article	IF	Citations
295	Promising Technologies in the Field of Helminth Vaccines. Frontiers in Immunology, 2021, 12, 711650.	4.8	24
296	Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates. Viruses, 2021, 13, 1645.	3.3	8
298	An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era. Pathogens, 2021, 10, 1030.	2.8	33
300	Perioperative Coronavirus Vaccinationâ€"Timing and Implications: A Guidance Document. Annals of Thoracic Surgery, 2021, 112, 1707-1715.	1.3	14
301	ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance. EClinicalMedicine, 2021, 38, 101027.	7.1	39
302	Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems. Drugs and Therapy Perspectives, 2021, 37, 376-382.	0.6	30
303	Impact of Prior Infection on Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in Syrian Hamsters. Frontiers in Microbiology, 2021, 12, 722178.	3.5	5
306	Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms. International Immunopharmacology, 2021, 97, 107679.	3.8	9
307	Predictive analysis of COVID-19 eradication with vaccination in India, Brazil, and U.S.A. Infection, Genetics and Evolution, 2021, 92, 104834.	2.3	16
308	The Efficacy of COVID-19 Vaccines in Chronic Kidney Disease and Kidney Transplantation Patients: A Narrative Review. Vaccines, 2021, 9, 885.	4.4	57
309	Comparing Results of Five SARS-CoV-2 Antibody Assays Before and After the First Dose of ChAdOx1 nCoV-19 Vaccine among Health Care Workers. Journal of Clinical Microbiology, 2021, 59, e0110521.	3.9	21
310	Cutaneous and hypersensitivity reactions associated with COVID-19 vaccinationâ€"aÂnarrative review. Wiener Medizinische Wochenschrift, 2021, , 1.	1.1	11
311	AACC Practical Recommendations for Implementing and Interpreting SARS-CoV-2 Emergency Use Authorization and Laboratory-Developed Test Serologic Testing in Clinical Laboratories. Clinical Chemistry, 2021, 67, 1188-1200.	3.2	20
314	Shell-mediated phagocytosis to reshape viral-vectored vaccine-induced immunity. Biomaterials, 2021, 276, 121062.	11.4	12
315	B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19). Nauchno-Prakticheskaya Revmatologiya, 2021, 59, 384-393.	1.0	12
316	Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies. Biomedicines, 2021, 9, 1163.	3.2	18
317	Evaluating the effectiveness of control measures in multiple regions during the early phase of the COVID-19 pandemic in 2020. Biosafety and Health, 2021, 3, 264-275.	2.7	11
318	A Self-Biomineralized Novel Adenovirus Vectored COVID-19 Vaccine for Boosting Immunization of Mice. Virologica Sinica, 2021, 36, 1113-1123.	3.0	11

#	Article	IF	Citations
319	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet, The, 2021, 398, 856-869.	13.7	430
320	Heterologous prime-boost regimens with HAdV-5 and NDV vectors elicit stronger immune responses to Ebola virus than homologous regimens in mice. Archives of Virology, 2021, 166, 3333-3341.	2.1	5
321	COVID-19 Vaccine: A Way Out of Crisis. , 0, , .		0
322	Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report. Vaccines, 2021, 9, 1031.	4.4	16
323	How the Global COVID-19 Pandemic Brought Drug and Vaccine Development into the Public Mainstream. Pharmaceutical Medicine, 2021, 35, 287-295.	1.9	1
325	Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques. Science Advances, 2021, 7, eabg7996.	10.3	20
326	Key points to keep in mind related to COVID-19 vaccines in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 54, 103142.	2.0	1
327	A comprehensive analysis of the efficacy and safety of COVID-19 vaccines. Molecular Therapy, 2021, 29, 2794-2805.	8.2	105
328	Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. Biomedicines, 2021, 9, 1303.	3.2	87
329	Prenatal care providersâ€™ perceptions of the SARS-Cov-2 vaccine for themselves and for pregnant women. PLoS ONE, 2021, 16, e0256080.	2.5	12
330	Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2. IScience, 2021, 24, 102941.	4.1	39
331	The Immune Response to SARS-CoV-2 and Variants of Concern. Viruses, 2021, 13, 1911.	3.3	18
332	An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates. Cell Host and Microbe, 2021, 29, 1437-1453.e8.	11.0	53
333	Universally Immune: How Infection Permissive Next Generation Influenza Vaccines May Affect Population Immunity and Viral Spread. Viruses, 2021, 13, 1779.	3.3	5
334	Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2. Journal of Virology, 2021, 95, e0097421.	3.4	12
335	COVID-19: Post-vaccine Smell and Taste Disorders: Report of 6 Cases. Ear, Nose and Throat Journal, 2024, 103, NP104-NP107.	0.8	26
336	Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters. PLoS ONE, 2021, 16, e0257191.	2.5	19
338	Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. International Immunology, 2021, 33, 529-540.	4.0	28

#	Article	IF	Citations
339	COVID-19 Animal Models and Vaccines: Current Landscape and Future Prospects. Vaccines, 2021, 9, 1082.	4.4	8
340	Changes in severity, mortality, and virus genome among a Spanish cohort of patients hospitalized with SARS-CoV-2. Scientific Reports, 2021, 11, 18844.	3.3	10
341	Organizational aspects of vaccination against a new coronavirus infection. NacionalÊ¹noe Zdravoohranenie, 2021, 2, 5-11.	1.2	2
342	COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions. Frontiers in Cellular and Infection Microbiology, 2021, 11, 690621.	3.9	60
343	Safety and immunogenicity of a QazCovid-inÂ® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan. EClinicalMedicine, 2021, 39, 101078.	7.1	37
344	SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review. International Journal of Biological Macromolecules, 2021, 188, 740-750.	7.5	83
345	Controversy surrounding the Sputnik V vaccine. Respiratory Medicine, 2021, 187, 106569.	2.9	28
346	Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina. EClinicalMedicine, 2021, 40, 101126.	7.1	60
347	Administration of COVID-19 vaccines in immunocompromised patients. International Immunopharmacology, 2021, 99, 108021.	3.8	51
348	COVID-19 pandemics Stage II â€“ Energy and environmental impacts of vaccination. Renewable and Sustainable Energy Reviews, 2021, 150, 111400.	16.4	65
350	A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. International Immunopharmacology, 2021, 100, 108162.	3.8	65
351	A nanoenzyme linked immunochromatographic sensor for rapid and quantitative detection of SARS-CoV-2 nucleocapsid protein in human blood. Sensors and Actuators B: Chemical, 2021, 349, 130718.	7.8	34
352	Carbohydrates-based diagnosis, prophylaxis and treatment of infectious diseases: Special emphasis on COVID-19. Carbohydrate Polymer Technologies and Applications, 2021, 2, 100052.	2.6	7
353	E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies. Journal of Molecular Graphics and Modelling, 2021, 109, 108035.	2.4	52
354	Operation Warp Speed: Projects responding to the COVID-19 pandemic. Project Leadership and Society, 2021, 2, 100019.	3.7	29
355	Comparative Analysis of SARS-CoV-2-Specific B Cell and Humoral Responses Elicited by Sputnik V in NaÃ¯ve and COVID-19-Recovered Vaccine Recipients. SSRN Electronic Journal, 0, , .	0.4	0
356	The COVID-19 vaccine: A race nearing the finish line. Apollo Medicine, 2021, .	0.0	1
357	COVID-19 vaccine: an overview of the progression and current use. Ä°stanbul Kuzey Klinikleri, 2021, 8, 529-536.	0.3	0

#	Article	IF	Citations
358	Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19. Emerging Microbes and Infections, 2021, 10, 1574-1588.	6.5	18
359	Overview of approved and upcoming vaccines for SARS-CoV-2: a living review. Oxford Open Immunology, 2021, 2, iqab010.	2.8	18
360	Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact. Immunotherapy Advances, 2021, 1, .	3.0	14
361	SARS-CoV-2 Antibody Response Following SPUTNIK V Vaccination in Healthcare Workers From a Hospital in Argentina: Preliminary Results. SSRN Electronic Journal, 0, , .	0.4	2
362	What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021. Journal of Korean Medical Science, 2021, 36, e54.	2.5	24
363	Current State of the First COVID-19 Vaccines. Vaccines, 2021, 9, 30.	4.4	64
364	T cell response to SARS-CoV-2 infection in humans: A systematic review. PLoS ONE, 2021, 16, e0245532.	2.5	228
365	A comprehensive overview of vaccines developed for pandemic viral pathogens over the past two decades including those in clinical trials for the current novel SARS-CoV-2. RSC Advances, 2021, 11, 20006-20035.	3.6	6
366	A Bioelectromagnetic Proposal Approaching the Complex Challenges of COVID-19. Open Journal of Biophysics, 2021, 11, 1-67.	0.5	1
367	Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages. Immune Network, 2021, 21, e4.	3.6	26
368	Sex Differences in Immunity: Implications for the Development of Novel Vaccines Against Emerging Pathogens. Frontiers in Immunology, 2020, 11, 601170.	4.8	33
369	Topical issues of diagnostics, examination and treatment of patients with COVID-19-associated pneumonia in different countries and continents. Meditsinskiy Sovet, 2021, , 96-102.	0.5	15
370	Advances in vaccination to combat pandemic outbreaks. , 2021, , 123-137.		1
371	Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses. Frontiers in Immunology, 2020, 11, 607333.	4.8	21
372	The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role. Oxford Open Immunology, 2021, 2, .	2.8	59
373	Researchers highlight â€˜questionableâ€™ data in Russian coronavirus vaccine trial results. Nature, 2020, 585, 493-493.	27.8	5
374	Human species D adenovirus hexon capsid protein mediates cell entry through a direct interaction with CD46. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	45
375	SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response. Open Forum Infectious Diseases, 2021, 8, ofaa555.	0.9	66

#	Article	IF	Citations
382	COVID-19 vaccines - are we there yet?. Australian Prescriber, 2021, 44, 19-25.	1.0	15
383	Experience in Studying Seroprevalence to SARS-CoV-2 Virus in the Population of the Irkutsk Region during COVID-19 Outbreak. Problemy Osobo Opasnykh Infektsii, 2020, , 106-113.	0.6	19
384	Nature Of, Immune Reaction and Side Effects of COVID-19 Vaccines: Synthesis of Information from Ten Phase II Trials for Planning Vaccination Programmes. SSRN Electronic Journal, 0, , .	0.4	3
385	Analysis of Promising Approaches to COVID-19 Vaccine Development. BIOpreparations Prevention Diagnosis Treatment, 2020, 20, 216-227.	0.5	10
386	Russian and International Regulatory Recommendations for the Development and Marketing Authorisation of COVID-19 Vaccines in the Context of the Pandemic. BIOpreparations Prevention Diagnosis Treatment, 2020, 20, 228-244.	0.5	1
387	Vaccines against Covid-19: the Comparative Estimates of Risks in Adenovirus Vectors. Epidemiologiya I Vaktsinoprofilaktika, 2020, 19, 4-17.	0.8	8
388	The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. International Journal of Molecular Sciences, 2020, 21, 9775.	4.1	40
389	Viral Vector Vaccines against Bluetongue Virus. Microorganisms, 2021, 9, 42.	3.6	14
390	Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval. Viruses, 2021, 13, 54.	3.3	61
391	Harnessing Cellular Immunity for Vaccination against Respiratory Viruses. Vaccines, 2020, 8, 783.	4.4	13
392	Advances in Oral Subunit Vaccine Design. Vaccines, 2021, 9, 1.	4.4	102
393	Platforms Exploited for SARS-CoV-2 Vaccine Development. Vaccines, 2021, 9, 11.	4.4	17
394	Plant-Based Drugs and Vaccines for COVID-19. Vaccines, 2021, 9, 15.	4.4	34
395	Efficacy and safety of COVID-19 vaccines: a systematic review. Chinese Journal of Contemporary Pediatrics, 2021, 23, 221-228.	0.2	81
397	An updated review on potential therapeutic drug candidates, vaccines and an insight on patents filed for COVID-19. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100063.	3.6	7
398	Optimal Vaccine Roll-Out Strategies with Respect to Social Distancing Measures for SARS-CoV-2 Pandemic. SSRN Electronic Journal, 0, , .	0.4	0
399	SARS-CoV-2: Pathogenic Mechanisms and Host Immune Response. Advances in Experimental Medicine and Biology, 2021, 1313, 99-134.	1.6	6
400	Implications for clinical dental practice during the coronavirus disease pandemic: A scoping review. Journal of Prosthodontic Research, 2022, 66, 6-11.	2.8	4

#	Article	IF	Citations
401	Adenoviral vectorâ€based platforms for developing effective vaccines to combat respiratory viral infections. Clinical and Translational Immunology, 2021, 10, e1345.	3.8	14
402	A Single Dose of a Hybrid hAdV5-Based Anti-COVID-19 Vaccine Induces a Long-Lasting Immune Response and Broad Coverage against VOC. Vaccines, 2021, 9, 1106.	4.4	5
403	COVID-19 Vaccines: Adenoviral Vectors. Annual Review of Medicine, 2022, 73, 41-54.	12.2	46
404	Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform. Nano Research, 2022, 15, 2196-2225.	10.4	8
405	Long Term Immune Response Produced by the SputnikV Vaccine. International Journal of Molecular Sciences, 2021, 22, 11211.	4.1	9
408	Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle Vaccines. Vaccines, 2021, 9, 1129.	4.4	26
409	WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community. Lancet Microbe, The, 2022, 3, e235-e240.	7.3	108
410	Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants. Expert Review of Vaccines, 2022, 21, 47-67.	4.4	3
411	Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments. Current Molecular Medicine, 2022, 22, 621-639.	1.3	2
412	COVID-19 Vaccine Platforms: Challenges and Safety Contemplations. Vaccines, 2021, 9, 1196.	4.4	15
413	Susceptibility of Dog, Hamster, and Mouse Cells to the Replication-Competent Adenovirus 11p E1/E3 Green Fluorescence Protein Vector Has Implications for the Selection of Animal Vaccine Models. Frontiers in Microbiology, 2021, 12, 698999.	3.5	1
414	Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. Vaccines, 2021, 9, 1195.	4.4	90
415	Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing. Ageing Research Reviews, 2022, 73, 101494.	10.9	11
416	Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2021, 12, 714170.	4.8	145
417	Comparative characteristics of COVID-19 vaccines used for mass immunisation. BIOpreparations Prevention Diagnosis Treatment, 2021, 21, 158-166.	0.5	6
419	A student led computational screening of peptide inhibitors against main protease of <scp>SARSâ€CoV</scp>â€2. Biochemistry and Molecular Biology Education, 2022, 50, 7-20.	1.2	4
420	Novel therapeutic drug strategies to tackle immune-oncological challenges faced by cancer patients during COVID-19. Expert Review of Anticancer Therapy, 2021, 21, 1371-1383.	2.4	12
421	Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic. International Journal of Pharmaceutics, 2021, 610, 121212.	5.2	11

#	Article	IF	Citations
422	GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults. Science Translational Medicine, 2022, 14, eabj1996.	12.4	18
423	Recent Update of COVID-19 Vaccines. Advanced Pharmaceutical Bulletin, 2021, , .	1.4	0
424	Development of synthetic antigen vaccines for COVID-19. Human Vaccines and Immunotherapeutics, 2021, 17, 3855-3870.	3.3	4
425	Assessment of T-cell immunity to SARS-CoV-2 in COVID-19 convalescents and vaccinated subjects, using TigraTest^{Â®} SARS-CoV-2 ELISPOT kit. BIOpreparations Prevention Diagnosis Treatment, 2021, 21, 178-192.	0.5	12
426	Nano-carriers of COVID-19 vaccines: the main pillars of efficacy. Nanomedicine, 2021, 16, 2377-2387.	3.3	8
427	SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies. International Immunopharmacology, 2021, 101, 108232.	3.8	14
428	Complete protection by a single-dose skin patchâ€"delivered SARS-CoV-2 spike vaccine. Science Advances, 2021, 7, eabj8065.	10.3	31
429	A Strategy for the Rapid Development of a Safe Vibrio cholerae Candidate Vaccine Strain. International Journal of Molecular Sciences, 2021, 22, 11657.	4.1	2
431	Guillain-Barre Syndrome and COVID-19 Vaccine: A Report of Nine Patients. Basic and Clinical Neuroscience, 2021, 12, 703-710.	0.6	24
433	Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. Cells, 2021, 10, 2949.	4.1	26
436	SARS-CoV-2 immunity and an overview of the COVID-19 vaccines. Medicinski Podmladak, 2021, 72, 20-29.	0.0	3
437	First real-world experience of Gam-COVID-Vac Sputnik V vaccine use. Profilakticheskaya Meditsina, 2021, 24, 53.	0.6	4
438	CORONAVIRUS VACCINE DEVELOPMENT: FROM SARS AND MERS TO COVID-19 (RUSSIAN TRANSLATION). Juvenis Scientia, 2020, 6, 41-80.	0.2	0
439	Prospects of vaccine against COVID-19. Indian Journal of Community Medicine, 2020, 45, 391.	0.4	2
440	Sputnik V Protection from COVID-19 of HIV-Infected Individuals Under Art. SSRN Electronic Journal, 0, , .	0.4	1
442	Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection). Clinics in Laboratory Medicine, 2022, 42, 111-128.	1.4	8
443	Prospects for improving immunoprophylaxis of infectious diseases. Vestnik of Russian Military Medical Academy, 2021, 23, 189-194.	0.3	0
444	SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence. Epidemiology and Infection, 2021, 149, 1-24.	2.1	43

#	Article	IF	Citations
445	Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy individuals: protocol for a systematic review and meta-analysis. BMJ Open, 2021, 11, e056106.	1.9	2
446	ASSESSMENT OF POPULATION IMMUNITY TO THE SARS-COV-2 VIRUS AMONG THE POPULATION OF GRODNO. Â½urnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta, 2021, 19, 489-495.	0.1	0
452	Efficacy and safety of potential vaccine candidates against coronavirus disease 2019: A systematic review. Journal of Advanced Pharmaceutical Technology and Research, 2021, 12, 215-221.	1.0	2
453	Viral-vectored vaccinesÂagainst SARS-CoV-2. , 2022, , 115-127.		1
454	Long-term analysis of antibodies elicited by SPUTNIK V: A prospective cohort study in TucumÃ¡n, Argentina. The Lancet Regional Health Americas, 2022, 6, 100123.	2.6	21
455	SARS-CoV-2: Overview and Its Impact on Oral Health. Biomedicines, 2021, 9, 1690.	3.2	7
456	Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. Nature Communications, 2021, 12, 6871.	12.8	147
457	Adenovirus vector-based vaccine for infectious diseases. Drug Metabolism and Pharmacokinetics, 2022, 42, 100432.	2.2	55
458	Ocular Manifestations after Receiving COVID-19 Vaccine: A Systematic Review. Vaccines, 2021, 9, 1404.	4.4	33
459	A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. Vaccines, 2021, 9, 1387.	4.4	51
460	Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges. Biomedicines, 2021, 9, 1740.	3.2	16
461	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. Seminars in Immunology, 2021, 55, 101533.	5.6	72
462	Safety and Seroconversion of Immunotherapies against SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis of Clinical Trials. Pathogens, 2021, 10, 1537.	2.8	19
464	Covidâ€19 vaccines and variants of concern: A review. Reviews in Medical Virology, 2022, 32, e2313.	8.3	201
465	COVID-19 vaccine confidence and hesitancy among health care workers: A cross-sectional survey from a MERS-CoV experienced nation. PLoS ONE, 2021, 16, e0244415.	2.5	63
466	Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran. International Immunopharmacology, 2021, 101, 108351.	3.8	36
467	Herd immunity to SARS-CoV-2 among the population of the Republic of Belarus amid the COVID-19 pandemic. Russian Journal of Infection and Immunity, 2021, 11, 887-904.	0.7	9
468	Ex VivoandIn VivoCD46 Receptor Utilization by Species D Human Adenovirus Serotype 26 (HAdV26). Journal of Virology, 2022, 96, JVI0082621.	3.4	9

#	Article	IF	Citations
469	Battle of COVID-19. Journal of Medical Academics, 2021, 4, 1-4.	0.1	0
470	Immunomodulation of COVIDâ€19 severity by helminth coâ€infection: Implications for COVIDâ€19 vaccine efficacy. Immunity, Inflammation and Disease, 2021, , .	2.7	10
471	The intestinal microbiota and improving the efficacy of COVID-19 vaccinations. Journal of Functional Foods, 2021, 87, 104850.	3.4	23
472	Heterologous primeâ€"boost strategies for COVID-19 vaccines. Journal of Travel Medicine, 2021, , .	3.0	37
473	Biotech, Biodefense and COVID-19 Vaccines in Russiaâ€™s National Security State. SSRN Electronic Journal, 0, , .	0.4	1
474	Motivation of COVID-19 Vaccination Among Hospital Employees: A National Survey. SSRN Electronic Journal, 0, , .	0.4	0
475	Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic. , 2021, 9, 251513552110597.	2.3	15
476	Seroprevalence of SARS-Cov-2 Antibodies in Adults, Arkhangelsk, Russia. Emerging Infectious Diseases, 2022, 28, 463-465.	4.3	3
477	Antibody responses induced by Sputnik V vaccine in individuals previously infected with SARS-CoV-2. The Lancet Regional Health Americas, 2022, 6, 100172.	2.6	0
478	Development of a high-throughput RT-PCR based viral infectivity assay for monitoring the stability of a replicating recombinant Lymphocytic Choriomeningitis viral vector. Journal of Virological Methods, 2022, 301, 114440.	2.1	1
479	Comparative analysis of existing platforms for the development of vaccines against dangerous and extremely dangerous viral infections with pandemic potential. BIOpreparations Prevention Diagnosis Treatment, 2021, 21, 225-233.	0.5	0
480	Approaches to quality control, preclinical and clinical studies of live recombinant viral vector vaccines. BIOpreparations Prevention Diagnosis Treatment, 2021, 21, 212-224.	0.5	0
481	Evaluation of short-term safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110615.	1.0	10
482	Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2. Cell and Bioscience, 2021, 11, 202.	4.8	13
483	La producciÃ³n y el flujo del conocimiento en la carrera internacional por las vacunas de COVID-19. Foro Internacional, 0, , 47-102.	0.2	2
484	Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time. MBio, 2022, 13, e0344221.	4.1	19
485	Immune Maturation Effects on Viral Neutralization and Avidity of Hyperimmunized Equine Anti-SARS-CoV-2 Sera. Antibodies, 2022, 11, 3.	2.5	1
486	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. Pharmacological Reviews, 2022, 74, 313-339.	16.0	9

#	Article	IF	Citations
487	Interleukin-1 Inhibitors and Vaccination Including COVID-19 in Inflammatory Rheumatic Diseases: A Nonsystematic Review. Frontiers in Immunology, 2021, 12, 734279.	4.8	5
488	An Outline of Contributing Vaccine Technologies for SARS CoV2 Advancing in Clinical and Preclinical Phase-Trials. Recent Patents on Biotechnology, 2022, 16, 122-143.	0.8	6
489	Covid-19 vaccines production and societal immunization under the serendipity-mindsponge-3D knowledge management theory and conceptual framework. Humanities and Social Sciences Communications, 2022, 9, .	2.9	85
490	COVID-19: Testing Landscape Post-Infection, -Vaccination, and Future Perspectives. Viral Immunology, 2022, 35, 5-14.	1.3	0
491	Cellular Immune Response after Vaccination in Patients with Cancerâ€"Review on Past and Present Experiences. Vaccines, 2022, 10, 182.	4.4	9
492	Long-term dynamics of the levels of anti-SARS-CoV-2 S-protein IgG antibodies in vaccinated individuals. Cardiovascular Therapy and Prevention (Russian Federation), 2022, 20, 3124.	1.4	7
493	Multi-Level Monitoring of Vaccination Adherence of Various Population Groups in the Context of the COVID-19 Pandemic: Problematic Issues. Epidemiologiya I Vaktsinoprofilaktika, 2022, 20, 28-36.	0.8	3
494	Risk Perception and Acceptability of the COVID-19 Vaccine in Nigeria. Turkish Journal of Pharmaceutical Sciences, 2022, 19, 686-693.	1.4	2
495	Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. Nature Medicine, 2022, 28, 401-409.	30.7	113
496	Boosting of the SARS-CoV-2â€"Specific Immune Response after Vaccination with Single-Dose Sputnik Light Vaccine. Journal of Immunology, 2022, 208, 1139-1145.	0.8	10
498	Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort. Vaccine, 2022, 40, 811-818.	3.8	9
499	Adenovirus-based vaccines and thrombosis in pregnancy: A systematic review and meta-analysis. Clinical Infectious Diseases, 2022, , .	5.8	6
500	Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac). Scientific Reports, 2022, 12, 1727.	3.3	11
501	Allergies and COVIDâ€19 vaccines: An ENDA/EAACI Position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2292-2312.	5.7	55
502	COVID-19 Compulsory Vaccination: Legal and Bioethical Controversies. Frontiers in Medicine, 2022, 9, 821522.	2.6	12
503	A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges. VirusDisease, 2022, 33, 1-22.	2.0	47
504	Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infectionâ€"A comparative study from Novi Sad, Serbia. PLoS ONE, 2022, 17, e0263468.	2.5	33
505	The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges. Journal of Infection and Public Health, 2022, 15, 228-240.	4.1	122

#	Article	IF	Citations
506	Vaccination policy and trust. Economic Modelling, 2022, 108, 105773.	3.8	13
507	COVID-19 vaccine therapeutic trials review: published results and registered protocols. Journal of Global Health Reports, 0, 5, .	1.0	0
509	Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines. Canadian Journal of Infectious Diseases and Medical Microbiology, 2022, 2022, 1-16.	1.9	2
510	Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Annals of Medicine, 2022, 54, 524-540.	3.8	225
511	Data and distrust hamper Russiaâ€™s vaccination programme. BMJ, The, 2022, 376, o321.	6.0	1
512	Neurological Immuneâ€Related Adverse Events After COVIDâ€19 Vaccination: A Systematic Review. Journal of Clinical Pharmacology, 2022, 62, 291-303.	2.0	23
513	A review of the safety and efficacy of current COVID-19 vaccines. Frontiers of Medicine, 2022, 16, 39-55.	3.4	19
514	The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. Human Vaccines and Immunotherapeutics, 2022, 18, 1-20.	3.3	163
516	An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants. Signal Transduction and Targeted Therapy, 2022, 7, 44.	17.1	31
517	Analytical characterization of the SARS-CoV-2 EURM-017 reference material. Clinical Biochemistry, 2022, 101, 19-25.	1.9	5
518	Immunogenicity and Safety of a 3-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Journal of Infectious Diseases, 2022, 225, 1701-1709.	4.0	9
521	Russian and Chinese vaccines. , 2022, , 71-77.		0
522	Biotechnology strategies for the development of novel therapeutics and vaccines against the novel COVID-19 pandemic. , 2022, , 205-226.		0
523	Drummondin E and Flinderole B are potential inhibitors of RNA-dependent RNA polymerase of SARS-CoV-2: an in silico study. Biotechnologia, 2022, 103, 53-70.	0.9	1
524	A Meta-Analysis on the Safety and Immunogenicity of Covid-19 Vaccines. Journal of Primary Care and Community Health, 2022, 13, 215013192210892.	2.1	21
525	An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962110566.	1.7	13
526	Fighting Fire with Fire: Immunogenicity of Viral Vectored Vaccines against COVID-19. Viruses, 2022, 14, 380.	3.3	4
527	E4orf1 Suppresses E1B-Deleted Adenovirus Vaccine-Induced Immune Responses. Vaccines, 2022, 10, 295.	4.4	2

#	Article	IF	Citations
528	Self-Assembled Particles Combining SARS-CoV-2 RBD Protein and RBD DNA Vaccine Induce Synergistic Enhancement of the Humoral Response in Mice. International Journal of Molecular Sciences, 2022, 23, 2188.	4.1	15
529	Novel Strategies of Immunization against COVID-19. Journal of Pure and Applied Microbiology, 2022, 16, 35-49.	0.9	0
531	Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants. International Journal of Environmental Research and Public Health, 2022, 19, 2392.	2.6	11
532	mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants. Scientific Reports, 2022, 12, 2628.	3.3	34
533	Vaccine Candidate Against COVID-19 Based on Structurally Modified Plant Virus as an Adjuvant. Frontiers in Microbiology, 2022, 13, 845316.	3.5	8
534	Side effects of COVID-19 vaccines: a systematic review and meta-analysis protocol of randomised trials. BMJ Open, 2022, 12, e050278.	1.9	21
535	Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review. Immunologic Research, 2022, 70, 289-315.	2.9	34
536	Seropositivity of SARS-CoV-2 in the Population of Kazakhstan: A Nationwide Laboratory-Based Surveillance. International Journal of Environmental Research and Public Health, 2022, 19, 2263.	2.6	3
537	Analysis of the effectiveness of vaccination against COVID-19 based on real-world data in St. Petersburg. Kachestvennaya Klinicheskaya Praktika, 2022, , 80-84.	0.5	3
538	The efficient development of a novel recombinant adenovirus zoster vaccine perfusion production process. Vaccine, 2022, 40, 2036-2043.	3.8	4
539	Immunogenic Epitope-Based Vaccine Prediction from Surface Glycoprotein of MERS-CoV by Deploying Immunoinformatics Approach. International Journal of Peptide Research and Therapeutics, 2022, 28, 77.	1.9	5
541	Post COVID-19 vaccination Guillain-Barre syndrome: three cases. Human Vaccines and Immunotherapeutics, 2022, 18, 1-5.	3.3	16
542	A systematic review on mucocutaneous presentations after COVIDâ€19 vaccination and expert recommendations about vaccination of important immuneâ€mediated dermatologic disorders. Dermatologic Therapy, 2022, 35, e15461.	1.7	31
543	A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates. Emerging Microbes and Infections, 2022, 11, 1058-1071.	6.5	63
544	Early Effectiveness of Four SARS-CoV-2 Vaccines in Preventing COVID-19 among Adults Aged â‰¥60 Years in Vojvodina, Serbia. Vaccines, 2022, 10, 389.	4.4	15
546	Probable treatment options for Covid-19: A brief review. IP International Journal of Comprehensive and Advanced Pharmacology, 2022, 7, 17-26.	0.3	0
547	Selection and Validation of siRNAs Preventing Uptake and Replication of SARS-CoV-2. Frontiers in Bioengineering and Biotechnology, 2022, 10, 801870.	4.1	13
548	Antibody responses to Sputnik Vaccination in naÃ¯ve and COVID 19-recovered vaccine recipients, India. Journal of Travel Medicine, 2022, 29, .	3.0	2

#	Article	IF	Citations
549	Covid-19: Ukraine conflict calls Russiaâ€™s vaccine diplomacy into question. BMJ, The, 2022, 376, o626.	6.0	4
550	On the Issue of Evaluating the Effectiveness of Vaccination of Employees of Medical Organizations against COVID-19. Epidemiologiya I Vaktsinoprofilaktika, 2022, 21, 61-66.	0.8	8
551	Various vaccine platforms in the field of COVID-19. Beni-Suef University Journal of Basic and Applied Sciences, 2022, 11, 35.	2.0	10
553	Covid-19 Vaccines Available in India. Combinatorial Chemistry and High Throughput Screening, 2022, 25, 2391-2397.	1.1	3
555	Human adenovirus type 26 basic biology and its usage as vaccine vector. Reviews in Medical Virology, 2022, 32, e2338.	8.3	4
557	Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis. Journal of Headache and Pain, 2022, 23, 41.	6.0	43
558	Oral SARS-CoV-2 Spike Protein Recombinant Yeast Candidate Prompts Specific Antibody and Gut Microbiota Reconstruction in Mice. Frontiers in Microbiology, 2022, 13, 792532.	3.5	11
559	Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapy. EClinicalMedicine, 2022, 46, 101360.	7.1	17
560	Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102482.	3.6	9
561	mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People. Viruses, 2022, 14, 748.	3.3	11
562	From Bench Side to Bed-Travelling on a Road to Get a Safe and Effective Vaccine against COVID-19, Day to Save the Life. Recent Patents on Biotechnology, 2022, 16, 2-5.	0.8	4
563	Outcomes of single dose COVID-19 vaccines: Eight month follow-up of a large cohort in Saudi Arabia. Journal of Infection and Public Health, 2022, 15, 573-577.	4.1	7
564	Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults. BMJ Open, 2022, 12, e056872.	1.9	12
565	A global survey in the developmental landscape of possible vaccination strategies for COVID-19. Clinical Immunology, 2022, 237, 108958.	3.2	11
566	Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2. JCI Insight, 2022, 7, .	5.0	13
567	Mutation hotspots of SARS-CoV-2 RNA motifs conserved in betacoronaviruses. Journal of Physics: Conference Series, 2021, 2099, 012037.	0.4	0
568	Immunogenic Properties of the DNA Construct Encoding the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein. Molecular Biology, 2021, 55, 889-898.	1.3	12
569	Molecular and Clinical Aspects of COVID-19 Vaccines and Other Therapeutic Interventions Apropos Emerging Variants of Concern. Frontiers in Pharmacology, 2021, 12, 778219.	3.5	0

#	Article	IF	Citations
570	Combinatorial Viral Vector-Based and Live Attenuated Vaccines without an Adjuvant to Generate Broader Immune Responses to Effectively Combat Pneumonic Plague. MBio, 2021, 12, e0322321.	4.1	6
571	Immunogenicity and safety of adenovirus-based vector vaccines for COVID-19: a systematic review and meta-analysis. Medical Journal of Indonesia, 2022, 30, 264-78.	0.5	1
572	Vaccination Against COVID-19: Emerging Issues and Future Prospects. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2021, 76, 652-660.	0.6	1
573	SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses. Npj Vaccines, 2021, 6, 151.	6.0	36
574	Vaccination against new coronavirus infection in patients with cardiovascular and autoimmune diseases. Complex Issues of Cardiovascular Diseases, 2021, 10, 112-121.	0.5	1
575	Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection. Cell Discovery, 2021, 7, 123.	6.7	10
576	Criteria for judging the immune markers of COVIDâ€19 disease vaccines. MedComm, 2022, 3, 1-12.	7.2	3
578	Results of the work of the Military medical academy research institute of novel coronavirus infection problems through 2020â€“2021. Vestnik of Russian Military Medical Academy, 2021, 23, 93-104.	0.3	17
579	Model-Based Planning and Delivery of Mass Vaccination Campaigns against Infectious Disease: Application to the COVID-19 Pandemic in the UK. Vaccines, 2021, 9, 1460.	4.4	8
580	Recent Advancements on COVID-19: A Comprehensive Review. International Journal of General Medicine, 2021, Volume 14, 10351-10372.	1.8	7
581	Advances in the design and development of SARS-CoV-2 vaccines. Military Medical Research, 2021, 8, 67.	3.4	26
583	COVID-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran. Vaccines, 2022, 10, 37.	4.4	15
584	VacunaciÃ³n contra SARS-CoV-2 / COVID-19: Actualidad y perspectivas de vacunaciÃ³n en Colombia. Pediatria, 2021, 54, 105-110.	0.2	0
585	Prevalence of Adverse Events Post-COVID-19 Vaccination amongst the Adult Zambian Population. Journal of Biomedical Research & Environmental Sciences, 2021, 2, 1315-1321.	0.2	1
586	Comparative Cohort Epidemiological Study of Collective Immunity against New Coronavirus Infection among Different Groups of Military Personnel. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2021, 76, 661-668.	0.6	14
587	COVID-19: The question of genetic diversity and therapeutic intervention approaches. Genetics and Molecular Biology, 2021, 44, e20200452.	1.3	1
588	â€œJust do what you canâ€: personal experience of medical university students working with COVID-19 patients. Sociology of Medicine, 2021, 20, 49-56.	0.4	0
589	Presence and quantity of antibodies after vaccination Â«Gam-COVID-VacÂ». Klinichescheskaya Laboratornaya Diagnostika, 2022, 67, 147-150.	0.5	2

#	Article	IF	Citations
590	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)â€“Specific T Cells and Antibodies in Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study. Clinical Infectious Diseases, 2022, 75, e1-e9.	5.8	25
591	Safety and immunogenicity of SpikoGenÂ®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations. Clinical Microbiology and Infection, 2022, 28, 1263-1271.	6.0	37
593	Global Scientific Research on SARS-CoV-2 Vaccines: A Bibliometric Analysis. Cell Journal, 2021, 23, 523-531.	0.2	4
594	Relationship between blood clots and COVID-19 vaccines: A literature review. Open Life Sciences, 2022, 17, 401-415.	1.4	6
595	Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population. Viruses, 2022, 14, 913.	3.3	5
596	The impact of vaccination against the new coronavirus infection on the morbidity of university students. Russian Family Doctor, 2022, 26, 21-26.	0.1	0
597	Epidemiological Features of COVID-19 in Northwest Russia in 2021. Viruses, 2022, 14, 931.	3.3	7
598	Development of a smartphone-based quantum dot lateral flow immunoassay strip for ultrasensitive detection of anti-SARS-CoV-2 IgG and neutralizing antibodies. International Journal of Infectious Diseases, 2022, 121, 58-65.	3.3	19
599	Evaluation of effectiveness of humoral immune response after vaccination with â€˜CoviVaÑâ€™. Medical Alphabet, 2022, 1, 18-24.	0.2	2
600	Recent developments in SARSâ€CoVâ€2 vaccines: A systematic review of the current studies. Reviews in Medical Virology, 2023, 33, e2359.	8.3	17
601	COVID-19 Vaccines and the Efficacy of Currently Available Vaccines Against COVID-19 Variants. Cureus, 2022, , .	0.5	3
602	Efficacy versus abundancy: Comparing vaccination schemes. PLoS ONE, 2022, 17, e0267840.	2.5	3
603	Vaccine Side Effects Following COVID-19 Vaccination Among the Residents of the UAEâ€"An Observational Study. Frontiers in Public Health, 2022, 10, .	2.7	50
604	COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduction and Targeted Therapy, 2022, 7, 146.	17.1	153
605	Vaccines for Covidâ€19: An insight on their effectiveness and adverse effects. Journal of Medical Virology, 2022, , .	5.0	7
606	COVID-19 Vaccine Hesitancy Among Older Adolescents and Young Adults: A National Cross-Sectional Study in China. Frontiers in Public Health, 2022, 10, .	2.7	7
607	Development of a perfusion process for serum-free adenovirus vector herpes zoster vaccine production. AMB Express, 2022, 12, 58.	3.0	3
608	Anti-cancer Virotherapy in Russia: Lessons from the Past, Current Challenges and Prospects for the Future. Current Pharmaceutical Biotechnology, 2023, 24, 266-278.	1.6	3

#	Article	IF	Citations
609	Immunoinformatic paradigm predicts macrophage and T-cells epitope responses against globally conserved spike fragments of SARS CoV-2 for universal vaccination. International Immunopharmacology, 2022, , 108847.	3.8	0
610	Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial. The Lancet Regional Health - Western Pacific, 2022, 24, 100474.	2.9	13
611	Neutralization assays for SARS-CoV-2: Implications for assessment of protective efficacy of COVID-19 vaccines. Indian Journal of Medical Research, 2022, 155, 105.	1.0	2
612	Comparison of severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine side effects by age groups. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2022, 68, 476-481.	0.7	3
613	The chimera of S1 and N proteins of SARS-CoV-2: can it be a potential vaccine candidate for COVID-19?. Expert Review of Vaccines, 2022, 21, 1071-1086.	4.4	3
614	Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial. PLoS Medicine, 2022, 19, e1003953.	8.4	27
615	Viral vector vaccines. Current Opinion in Immunology, 2022, 77, 102210.	5.5	28
616	COVID-19: VARIANTS, VACCINES, AND ADVERSE REACTIONS. Innovare Journal of Medical Sciences, 0, , 6-13.	0.2	0
617	Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities. Medical Review, 2022, 2, 169-196.	1.2	5
618	Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models. Molecular Immunology, 2022, 149, 107-118.	2.2	2
620	COVID-19 exit strategy during vaccine implementation: a balance between social distancing and herd immunity. Archives of Virology, 0, , .	2.1	1
621	Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharmâ€™s COVID-19 Vaccines. Frontiers in Immunology, 0, 13, .	4.8	33
623	Concerns and Challenges Related to Sputnik V Vaccination Against the Novel COVID-19 Infection in the Russian Federation: The Role of Mental Health, and Personal and Social Issues as Targets for Future Psychosocial Interventions. Frontiers in Psychiatry, 0, 13, .	2.6	2
624	Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance. Vaccines, 2022, 10, 938.	4.4	15
625	The State-of-the-Art of Gene Editing and its Application to Viral Infections and Diseases Including COVID-19. Frontiers in Cellular and Infection Microbiology, 0, 12, .	3.9	5
626	Is the COVID-19 Pandemic Over? The Current Status of Boosters, Immunosenescence, Long Haul COVID, and Systemic Complications. International Journal of Translational Medicine, 2022, 2, 230-241.	0.4	0
627	Optimal vaccine roll-out strategies including social distancing for pandemics. IScience, 2022, 25, 104575.	4.1	5
628	Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population. MBio, 2022, 13, .	4.1	9

#	Article	IF	Citations
629	COVID-19 Vaccines: Update of the vaccines in use and under development. Vacunas, 2022, , .	2.0	6
630	Long-term antibody response following SPUTNIK V primary vaccination in healthcare workers with and without history of SARS-CoV-2 infection: Prospective cohort study from a hospital in Argentina. Vaccine: X, 2022, 11, 100187.	2.1	4
631	Decavanadate interactions with the elements of the SARS-CoV-2 spike protein highlight the potential role of electrostatics in disrupting the infectivity cycle. Journal of Inorganic Biochemistry, 2022, 234, 111899.	3.5	7
632	COVID-19 vaccines portray the bright side of human creativity, but it means nothing until they prove their worth: A Study on Seroconversion after the first Dose of Covishield vaccine in central Kerala. Indian Journal of Community Medicine, 2022, 47, 213.	0.4	0
633	Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China. Virologica Sinica, 2022, 37, 716-723.	3.0	5
634	Coronavirus Disease 2019 Vaccination for Cancer Patients: Risk or Benefit?. Revista Brasileira De Ginecologia E Obstetricia, 2022, 44, 602-608.	0.8	1
635	Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice. Emerging Microbes and Infections, 2022, 11, 1890-1899.	6.5	12
636	Viral Vector Vaccine Development and Application during the COVID-19 Pandemic. Microorganisms, 2022, 10, 1450.	3.6	28
637	Global Trends in Nursing-Related Research on COVID-19: A Bibliometric Analysis. Frontiers in Public Health, 0, 10, .	2.7	11
638	Investigating trends in those who experience menstrual bleeding changes after SARS-CoV-2 vaccination. Science Advances, 2022, 8, .	10.3	68
639	A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens. Pharmaceutical Research, 2022, 39, 2119-2134.	3.5	10
640	The impact of COVID-19 vaccination programme in the Republic of San Marino: Focus on effectiveness of Gam-Covid-Vac. Clinical Microbiology and Infection, 2022, 28, 1636-1643.	6.0	3
641	Assessment of post-vaccination collective immunity against new coronavirus infection (COVID-19) among servicemen of the Armed Forces of the Russian Federation. Vestnik of Russian Military Medical Academy, 2022, 24, 267-276.	0.3	3
642	SARS-CoV-2 herd immunity of the Kyrgyz population in 2021. Medical Microbiology and Immunology, 2022, 211, 195-210.	4.8	8
643	Insights into COVID-19 vaccines development: Translation from benchside to bedside. Health Sciences Review, 2022, 4, 100040.	1.5	1
644	Vacunas contra la COVID-19. Ambiociencias, 0, , 75-108.	0.0	1
645	Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review. Infectious Disease Reports, 2022, 14, 537-546.	3.1	23
646	A bibliometric analysis of COVID-19 publications in neurology by using the visual mapping method. Frontiers in Public Health, 0, 10, .	2.7	14

#	Article	IF	Citations
647	Report of Adverse Effects Following Population-Wide COVID-19 Vaccination: A Comparative Study between Six Different Vaccines in Baja-California, Mexico. Vaccines, 2022, 10, 1196.	4.4	3
648	Perspectives on Genetic Medicine for Cystic Fibrosis. Current Gene Therapy, 2022, 22, .	2.0	0
649	The Analysis of Anti-Epidemic Measures Carried Out in the Russian Federation in the Context of the COVID-19 Pandemic. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2022, 77, 172-180.	0.6	0
650	A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigen-specific cellular immune responses. Human Vaccines and Immunotherapeutics, 2022, 18, .	3.3	4
651	Drug hypersensitivity, in vitro tools, biomarkers, and burden with <scp>COVID</scp>â€19 vaccines. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3527-3537.	5.7	2
652	SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	28
653	Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study. Scientific Reports, 2022, 12, .	3.3	12
654	Clinical and immunological characteristics of vaccinated patients with COVID-19. Chinese Medical Journal, 0, Publish Ahead of Print, .	2.3	0
655	Integrase deficient lentiviral vector: prospects for safe clinical applications. PeerJ, 0, 10, e13704.	2.0	6
656	Evaluation of response to different COVIDâ€19 vaccines in vaccinated healthcare workers in a single center in Iran. Journal of Medical Virology, 2022, 94, 5669-5677.	5.0	6
657	Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques. Frontiers in Immunology, 0, 13, .	4.8	2
658	Latest in COVID-19 Vaccine 'Candidates' Race. Infectious Disorders - Drug Targets, 2022, 22, .	0.8	0
659	Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates. Emerging Microbes and Infections, 2022, 11, 2229-2247.	6.5	8
660	The Sputnik V moment: biotech, biowarfare and COVID-19 vaccine development in Russia and in former Soviet satellite states. East European Politics, 2022, 38, 571-593.	1.5	3
661	Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approach. EBioMedicine, 2022, 84, 104264.	6.1	4
662	COVID-19: Vaccines and therapeutics. Bioorganic and Medicinal Chemistry Letters, 2022, 75, 128987.	2.2	4
663	Hazards of vaccinating the way out of Covid-19 pandemic: Study of adverse events following immunization (Aefi) in India. Medical Journal of Dr D Y Patil Vidyapeeth, 2022, .	0.1	0
664	Development of Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-COV-2) Vaccines. Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria, 2022, 31, 484.	0.1	0

#	Article	IF	Citations
665	SARS-CoV-2 Vaccine Against Virus: Mission Accomplished!?. , 2022, , 561-574.		0
666	Acute Ischemic Stroke in the Context of SARS-CoV-2 Vaccination: A Systematic Review. Neuropsychiatric Disease and Treatment, 0, Volume 18, 1907-1916.	2.2	3
667	Is Russiaâ€™s Research Ethics Culture Reliable?. Ethics & Human Research, 0, , .	0.9	0
668	Identification of the effects of COVID-19 on patients with pulmonary fibrosis and lung cancer: a bioinformatics analysis and literature review. Scientific Reports, 2022, 12, .	3.3	6
669	Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic. Frontiers in Immunology, 0, 13, .	4.8	2
670	Vaccine effectiveness against referral to hospital after SARS-CoV-2 infection in St. Petersburg, Russia, during the Delta variant surge: a test-negative case-control study. BMC Medicine, 2022, 20, .	5.5	8
671	COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 during Delta variant surge: a preliminary assessment from a case-control study in St.ÂPetersburg, Russia. BMC Public Health, 2022, 22, .	2.9	4
672	COVID-19 Vaccinating Russian Medical Studentsâ€"Challenges and Solutions: A Cross-Sectional Study. International Journal of Environmental Research and Public Health, 2022, 19, 11556.	2.6	2
673	COVID-19 Infection Risk Following Elective Arthroplasty and Surgical Complications in COVID-19-vaccinated Patients: A Multicenter Comparative Cohort Study. Arthroplasty Today, 2022, 18, 76-83.	1.6	4
674	Gene Therapy Cargoes Based on Viral Vector Delivery. Current Gene Therapy, 2023, 23, 111-134.	2.0	5
675	A critical overview of current progress for COVID-19: development of vaccines, antiviralÂdrugs, and therapeutic antibodies. Journal of Biomedical Science, 2022, 29, .	7.0	64
676	Development of variantâ€proof severe acute respiratory syndrome coronavirus 2, panâ€sarbecovirus, and panâ€Î²â€coronavirus vaccines. Journal of Medical Virology, 2023, 95, .	5.0	12
677	A novel vaccine based on SARS-CoV-2 CD4+ and CD8+ T cell conserved epitopes from variants Alpha to Omicron. Scientific Reports, 2022, 12, .	3.3	8
678	A Hitchhiker's Guide to Worldwide COVID-19 Vaccinations: A Detailed Review of Monovalent and Bivalent Vaccine Schedules, COVID-19 Vaccine Side Effects, and Effectiveness Against Omicron and Delta Variants. Cureus, 2022, , .	0.5	10
679	The use of adenoviral vectors in gene therapy and vaccine approaches. Genetics and Molecular Biology, 2022, 45, .	1.3	3
680	Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity. Journal of Clinical Investigation, 2022, 132, .	8.2	12
681	A comprehensive review on variants of SARS-CoVs-2: Challenges, solutions and open issues. Computer Communications, 2023, 197, 34-51.	5.1	13
683	A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants. Vaccines, 2022, 10, 1655.	4.4	12

#	Article	IF	Citations
684	Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. Vaccines, 2022, 10, 1751.	4.4	10
685	Sputnik Light and Sputnik V Vaccination Is Effective at Protecting Medical Personnel from COVID-19 during the Period of Delta Variant Dominance. Vaccines, 2022, 10, 1804.	4.4	9
686	Association of COVID-19 Vaccinations With Intensive Care Unit Admissions and Outcome of Critically Ill Patients With COVID-19 Pneumonia in Lombardy, Italy. JAMA Network Open, 2022, 5, e2238871.	5.9	19
687	Analysis and comparison of anti-RBD neutralizing antibodies from AZD-1222, Sputnik V, Sinopharm and Covaxin vaccines and its relationship with gender among health care workers. Immunity and Ageing, 2022, 19, .	4.2	5
688	Peptide ILE-GLU-TRP (Stemokin) Potential Adjuvant Stimulating a Balanced Immune Response. International Journal of Peptide Research and Therapeutics, 2022, 28, .	1.9	1
689	Importance of the COVID-19 Vaccine Booster Dose in Protection and Immunity. Vaccines, 2022, 10, 1708.	4.4	3
690	An ELISA Platform for the Quantitative Analysis of SARS-CoV-2 RBD-neutralizing Antibodies As an Alternative to Monitoring of the Virus-Neutralizing Activity. , 2022, 14, 109-119.		2
691	An Analysis of the COVID-19 Situation in India in Terms of Testing, Treatment, Vaccine Acceptance and National Economic Performance. International Journal of Public Health, 0, 67, .	2.3	1
692	Role of next-generation sequencing in diagnosing, tracking and vaccine development of severe acute respiratory syndrome coronavirus 2. Journal of the Academy of Clinical Microbiologists, 2022, 24, 25.	0.1	0
693	SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines. Science Immunology, 2022, 7, .	11.9	42
694	Vaccines for the Prevention of Coronavirus Disease 2019 in Older Adults. Infectious Disease Clinics of North America, 2023, 37, 27-45.	5.1	6
695	Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities. Npj Vaccines, 2022, 7, .	6.0	10
696	An attenuated vaccinia vaccine encoding the severe acute respiratory syndrome coronavirus-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human angiotensin-converting enzyme 2 transgenic mice from severe acute respiratory syndrome coronavirus-2 and its variants. Frontiers in Microbiology, 0, 13, .	3.5	4
697	Lessons learned from COVID-19 pandemic: Vaccine platform is a key player. Process Biochemistry, 2023, 124, 269-279.	3.7	2
698	COVID-19 signalome: Potential therapeutic interventions. Cellular Signalling, 2023, 103, 110559.	3.6	5
699	COVID-19 vaccines: Update of the vaccines in use and under development. Vacunas (English Edition), 2022, 23, S88-S102.	0.2	0
700	Presentations at the UK National Immunisation Conference. Human Vaccines and Immunotherapeutics, 2022, 18, .	3.3	1
701	Respiratory viral infections and their role in human cardiovascular diseases. Sibirskij Å¾urnal KliniÄeskoj I Ã¨ksperimentalÊ¹noj Mediciny, 0, , .	0.4	0

#	Article	IF	Citations
702	Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina. Vaccine, 2022, , .	3.8	0
703	130th anniversary of virology. Voprosy Virusologii, 2022, 67, 357-384.	0.7	2
704	Incubation Temperature and Period During Denarase Treatment and Microfiltration Affect the Yield of Recombinant Adenoviral Vectors During Downstream Processing. Molecular Biotechnology, 0, , .	2.4	0
705	Nasal vaccines: solutions for respiratory infectious diseases. Trends in Molecular Medicine, 2023, 29, 124-140.	6.7	10
706	Neurological Complications Following COVID-19 Vaccination. Current Neurology and Neuroscience Reports, 2023, 23, 1-14.	4.2	12
707	Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. Frontiers in Bioengineering and Biotechnology, 0, 10, .	4.1	3
709	Different Formulations of Inactivated SARS-CoV-2 Vaccine Candidates in Human Compatible Adjuvants: Potency Studies in Mice Showed Different Platforms of Immune Responses. Viral Immunology, 2022, 35, 663-672.	1.3	2
710	Knowledge And Attitudes Toward the COVID-19 Vaccine Among India's General Rural Population. Vacunas, 2022, , .	2.0	0
711	Nanotechnology in COVID-19 Vaccines. , 2023, , 14-26.		0
712	Ethical Evaluations of Clinical Trials in France: Towards European Standardization. Philosophy and Medicine, 2023, , 405-421.	0.3	0
713	Biphenyl furanocoumarin compounds inhibit SARS-CoV-2 spike pseudovirus infection by binding ACE2. New Journal of Chemistry, 2023, 47, 2651-2658.	2.8	1
714	Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines. Vaccines, 2023, 11, 101.	4.4	14
715	Full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice conferred by MVA-CoV2-S vaccine candidate. Nature Neuroscience, 2023, 26, 226-238.	14.8	14
716	COVID-19 Vaccinesâ€"All You Want to Know. Seminars in Respiratory and Critical Care Medicine, 2023, 44, 143-172.	2.1	4
717	Sperm DNA fragmentation in men vaccinated with Gam-COVID-Vac (Sputnik V). Andrologia I Genital'naa Hirurgia, 2023, 23, 64-73.	0.2	0
718	An experience of scaling and intensifying the industrial production of the Gam-COVID-Vac vector adenovirus vaccine in the limiting conditions of the pandemic. BIOpreparations Prevention Diagnosis Treatment, 2022, 22, 382-391.	0.5	0
719	Selection of a SARS-CoV-2 antibody quantification method and development of an antibody reference standard for ELISA to test immunoglobulin preparations. BIOpreparations Prevention Diagnosis Treatment, 2022, 22, 392-404.	0.5	0
720	Aspects and issues of marketing authorisation and use of medicinal products for COVID-19 prevention during the pandemic. BIOpreparations Prevention Diagnosis Treatment, 2022, 22, 361-381.	0.5	2

#	Article	IF	Citations
721	Immunogenicity evaluation of Gam-COVID-Vac (Sputnik V). BIOpreparations Prevention Diagnosis Treatment, 2022, 22, 435-445.	0.5	3
722	Cohort Profile:The Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 vaccines (ENFORCE). BMJ Open, 2022, 12, e069065.	1.9	5
723	Revaccination in Age-Risk Groups with Sputnik V Is Immunologically Effective and Depends on the Initial Neutralizing SARS-CoV-2 IgG Antibodies Level. Vaccines, 2023, 11, 90.	4.4	3
724	Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences, 2023, 24, 416.	4.1	1
725	History of vaccine: from centuries to present. , 2022, , 3-16.		0
726	Cancer vaccineâ€™s multiverse and the future ahead. , 2022, , 335-360.		0
727	Adverse events and SARS-CoV-2 antibody responses after immunization with Sputnik V, ChAdOx1-S, and BBIBP-CorV vaccines in people with HIV. Aids, 2023, 37, 941-946.	2.2	1
728	Immunogenicity Characterization of COVID-19 Vaccines: A Systematic Review and Meta-analysis. Revista Da Sociedade Brasileira De Medicina Tropical, 0, 56, .	0.9	2
729	The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics. Molecular Diagnosis and Therapy, 2023, 27, 193-226.	3.8	6
730	Evaluation of Short-Term Side Effects Following the First Dose of COVID-19 Vaccines Among Physicians and Dentists: A Cross-Sectional Study from India. Journal of Multidisciplinary Healthcare, 0, Volume 16, 161-174.	2.7	6
731	Applications of genetic engineering in COVID-19. , 2023, , 219-237.		0
732	COVID-19 Vaccination and Alcohol Consumption: Justification of Risks. Pathogens, 2023, 12, 163.	2.8	4
733	Combating the challenges of COVID-19 pandemic: Insights into molecular mechanisms, immune responses and therapeutics against SARS-CoV-2. Oxford Open Immunology, 2023, 4, .	2.8	3
734	Can COVID-19 Vaccines Induce Premature Non-Communicable Diseases: Where Are We Heading to?. Vaccines, 2023, 11, 208.	4.4	5
735	T-Cell Immunity in COVID-19-Recovered Individuals and Individuals Vaccinated with the Combined Vector Vaccine Gam-COVID-Vac. International Journal of Molecular Sciences, 2023, 24, 1930.	4.1	0
736	Thermostability of Vaccines. , 2023, , 33-79.		0
737	Reoccurrence of Covid-19 infection in vaccinated Iraqi community. AIP Conference Proceedings, 2023, , .	0.4	0
738	Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduction and Targeted Therapy, 2023, 8, .	17.1	23

#	Article	IF	Citations
739	Comparative assessment of efficacy and immunogenicity of Gam-COVID-Vac and CoviVac vaccines against SARS-CoV-2. Profilakticheskaya Meditsina, 2022, 25, 82.	0.6	1
740	Respiratory viral infections and their role in human cardiovascular diseases. Sibirskij Å¾urnal KliniÄeskoj I Ã¨ksperimentalÊ¹noj Mediciny, 2023, 37, 14-21.	0.4	0
741	An Overview of Current Accomplishments and Gaps of COVID-19 Vaccine Platforms and Considerations for Next Generation Vaccines. Journal of Pharmaceutical Sciences, 2023, 112, 1345-1350.	3.3	3
742	COVID-19 therapy and vaccination: a clinical narrative review. Drugs in Context, 0, 12, 1-11.	2.2	10
743	Assesment of specific T-cell immunity to SARS-CoV-2 virus antigens in COVID-19 reconvalescents. Voprosy Virusologii, 2023, 67, 527-537.	0.7	1
744	Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status. Vaccines, 2023, 11, 432.	4.4	17
745	Adverse events following immunisation with the first dose of sputnik V among Iranian health care providers. Clinical and Experimental Vaccine Research, 2023, 12, 25.	2.2	0
746	SARS-CoV-2 S Glycoprotein Stabilization Strategies. Viruses, 2023, 15, 558.	3.3	1
747	The Coming of Age of Nucleic Acid Vaccines during COVID-19. MSystems, 2023, 8, .	3.8	5
748	Preventive Efficacy of Domestic Vaccines against a New Coronavirus Infection in the Immunization of Employees of Medical Organizations. Epidemiologiya I Vaktsinoprofilaktika, 2023, 22, 22-27.	0.8	3
749	Investigating antigenic features of the SARS-CoV-2 isolated in Russian Federation in 2021â€“2022 by hyperimmune mouse serum neutralisation. Russian Journal of Infection and Immunity, 2023, 13, 37-45.	0.7	1
750	Dissection of Antibody Responses of Gam-COVID-Vac-Vaccinated Subjects Suggests Involvement of Epitopes Outside RBD in SARS-CoV-2 Neutralization. International Journal of Molecular Sciences, 2023, 24, 5104.	4.1	2
751	Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia. PLoS ONE, 2023, 18, e0278878.	2.5	1
753	Human memory T cell dynamics after aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccination. Scientific Reports, 2023, 13, .	3.3	0
755	rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19. Frontiers in Immunology, 0, 14, .	4.8	1
756	Dendrimer-Mediated Delivery of DNA and RNA Vaccines. Pharmaceutics, 2023, 15, 1106.	4.5	7
757	Vaccine Basics and the Development and Rollout of COVID-19 Vaccines. , 2024, , 326-348.		0
758	An assessment of the strategy and status of COVID-19 vaccination in India. Immunologic Research, 2023, 71, 565-577.	2.9	3

#	Article	IF	Citations
759	Longitudinal Follow-Up of the Immunity to SARS-CoV-2 in Health Care Workers in Argentina: Persistence of Humoral Response and Neutralizing Capacity after Sputnik V Vaccination. MSphere, 0, , .	2.9	0
760	Side Effects Comparison of Coronavirus Vaccines Among Healthcare Workers in Shoushtar, Iran. BMC Clinical Pathology, 2023, 16, 2632010X2311667.	1.7	1
761	Comparative analysis of humoral immune response upon the three first vaccines applied in Argentina: IgG production and neutralizing capacity against SARS-CoV-2. Heliyon, 2023, 9, e15211.	3.2	1
762	Research Advances in SARS-Cov-2 Vaccination of Bellâ€™s Palsy. Advances in Clinical Medicine, 2023, 13, 5965-5971.	0.0	0
763	Recombinant Bacillus Calmetteâ€“GuÃ©rin Expressing SARS-CoV-2 Chimeric Protein Protects K18-hACE2 Mice against Viral Challenge. Journal of Immunology, 2023, 210, 1925-1937.	0.8	6
764	Nanocarrier vaccine therapeutics for global infectious and chronic diseases. Materials Today, 2023, 66, 371-408.	14.2	8
765	Knowledge and attitudes toward the COVID-19 vaccine among India's general rural population. Vacunas (English Edition), 2023, 24, 128-134.	0.2	0
766	Modeling SARSâ€CoVâ€2 True Infections in Catalonia through a Digital Twin. Advanced Theory and Simulations, 2023, 6, .	2.8	2
767	A profound perception into manifestation of lifesaver. AIP Conference Proceedings, 2023, , .	0.4	0
768	The effect of COVID-19 on cancer immunotherapy and cancer care. , 2024, , 289-310.e7.		0
769	Antigenic Cartography Indicates That the Omicron BA.1 and BA.4/BA.5 Variants Remain Antigenically Distant to Ancestral SARS-CoV-2 after Sputnik V Vaccination Followed by Homologous (Sputnik V) or Heterologous (Comirnaty) Revaccination. International Journal of Molecular Sciences, 2023, 24, 10493.	4.1	0
770	Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from Greece. Vacunas, 2023, 24, 210-217.	2.0	1
771	Phenotypic Changes in T and NK Cells Induced by Sputnik V Vaccination. Vaccines, 2023, 11, 1047.	4.4	0
772	Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults: a randomized, double-blinded, immunobridging trial. Expert Review of Vaccines, 2023, 22, 662-670.	4.4	0
773	The role of vaccines in the COVID-19 pandemic: what have we learned?. Seminars in Immunopathology, 0, , .	6.1	13
774	Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from Greece. Vacunas (English Edition), 2023, 24, 210-217.	0.2	0
775	Bibliometric analysis of the highly cited publications in COVID-19 vaccine. Heliyon, 2023, 9, e18540.	3.2	0
776	Genetic-Based Vaccine Vectors. , 2023, , 1374-1396.e11.		0

#	Article	IF	Citations
777	Technologies for Making New Vaccines. , 2023, , 1350-1373.e9.		0
778	Coronavirus Vaccines. , 2023, , 248-257.e4.		0
779	Comprehensive Review of the Initial 11 WHO Emergency Use Listed COVID-19 Vaccine Candidates: Mechanisms, Efficacy, and Comparative Attributes for Safety and Well-Being. , 2023, 2, 138-158.		0
780	A China-developed adenovirus vector-based COVID-19 vaccine: review of the development and application of Ad5-nCov. Expert Review of Vaccines, 2023, 22, 704-713.	4.4	1
781	Attitudes towards vaccination against COVID-19 among athletes of Russian national teams in comparison with non-athletes aged 18 to 40. Sports Medicine Research and Practice, 2023, 13, 60-71.	0.2	0
782	Various reagent kits for comparatively analyzed effectiveness of humoral immune response after vaccination â€œSputnik V". Russian Journal of Infection and Immunity, 2023, 13, 469-480.	0.7	1
783	A Critical Assessment of COVID-19 Genomic Vaccines. Current Topics in Medicinal Chemistry, 2023, 23, .	2.1	0
784	Nanotechnology of inhalable vaccines for enhancing mucosal immunity. Drug Delivery and Translational Research, 0, , .	5.8	0
785	Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study. Frontiers in Immunology, 0, 14, .	4.8	2
786	Protection of COVID-19 vaccine in general and special population. , 2023, , .		0
788	Organizing the large multiple-center clinical trials based on modern digital approaches during the pandemic of a novel coronavirus infection in Moscow. Medical Technologies Assessment and Choice (ÐœÐµÐ´Ð¸Ñ†Ð¸Ð½Ñ•ÐºÐ¸Ðµ Ñ‚Ðµ	0.3	
790	Anxiety and Association with COVID-19 Vaccination-Related Headache Symptoms. , 2023, 6, 269-275.		0
791	An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines. Biomolecules, 2023, 13, 1565.	4.0	0
792	Enhanced protective efficacy of a thermostable RBD-S2 vaccine formulation against SARS-CoV-2 and its variants. Npj Vaccines, 2023, 8, .	6.0	1
793	Analysis of the protective efficacy of approved COVID-19 vaccines against Omicron variants and the prospects for universal vaccines. Frontiers in Immunology, 0, 14, .	4.8	2
794	Effectiveness of VSV vectored SARS-CoV-2 spike when administered through intranasal, intramuscular or a combination of both. Scientific Reports, 2023, 13, .	3.3	1
795	Evolution of SARS-CoV-2 Spikes shapes their binding affinities to animal ACE2 orthologs. Microbiology Spectrum, 2023, 11, .	3.0	0
797	Seroprevalence of human adenovirus type 5 neutralizing antibodies in the Philippines. PLoS ONE, 2023, 18, e0293046.	2.5	0

#	Article	IF	Citations
798	A lung-selective delivery of mRNA encoding broadly neutralizing antibody against SARS-CoV-2 infection. Nature Communications, 2023, 14, .	12.8	0
799	Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant. Nature Communications, 2023, 14, .	12.8	16
800	To be remembered: B cell memory response against <scp>SARSâ€CoV</scp>â€2 and its variants in vaccinated and unvaccinated individuals. Scandinavian Journal of Immunology, 0, , .	2.7	0
801	Real-Life Experience in the Efficacy and Safety of COVID-19 Vaccination in Patients with Advanced Cirrhosis. Journal of Clinical Medicine, 2023, 12, 7578.	2.4	0
802	Inactivated whole virion vaccine protects K18â€hACE2 Tg mice against the Omicron SARSâ€CoVâ€2 variant via crossâ€reactive T cells and nonneutralizing antibody responses. European Journal of Immunology, 0, , .	2.9	0
803	Construction of recombinant adenovirus-5 vector to prevent replication-competent adenovirus occurrence. Acta Virologica, 0, 67, .	0.8	0
804	Immune Responses Elicited by COVID-19 Vaccines. Asian Journal of Biological Sciences, 2023, 16, 89-102.	0.2	0
805	Evaluation of Immune Response to Mucosal Immunization with an Oral Probiotic-Based Vaccine in Mice: Potential for Prime-Boost Immunization against SARS-CoV-2. International Journal of Molecular Sciences, 2024, 25, 215.	4.1	0
806	Nasal cavity microbiota features among people who have had COVID-19. , 2023, 18, 97-102.		0
807	Neurological complications after covid-19 vaccination. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2023, 123, 13.	0.7	0
808	Reported side-effects following Oxford/AstraZeneca COVID-19 vaccine in the north-west province, Iran: A cross-sectional study. PLoS ONE, 2024, 19, e0296669.	2.5	0
809	Incidence of COVID-19 among Vaccinated with Sputnik V and CoviVac Vaccines (Results of the) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Vaktsinoprofilaktika, 2024, 22, 81-89.	0.8	0
810	Therapeutic landscape of SARS-CoV-2. , 2024, , 83-99.		0
811	Expanded specific TÂcells to hypomutated regions of the SARS-CoV-2 using mRNA electroporated antigen-presenting cells. Molecular Therapy - Methods and Clinical Development, 2024, 32, 101192.	4.1	0
812	COVID-19 Vaccines: Where Did We Stand at the End of 2023?. Viruses, 2024, 16, 203.	3.3	0
813	Development of NP-Based Universal Vaccine for Influenza A Viruses. Vaccines, 2024, 12, 157.	4.4	0
814	Enhancing Immunological Memory: Unveiling Booster Doses to Bolster Vaccine Efficacy Against Evolving SARS-CoV-2 Mutant Variants. Current Microbiology, 2024, 81, .	2.2	0
815	Role of homologous recombination/recombineering on human adenovirus genome engineering: Not the only but the most competent solution. Engineering Microbiology, 2024, 4, 100140.	4.7	0

#	Article	IF	Citations
816	Severity and duration of immune response in people of different age categories after SARS-CoV-2 revaccination. Cardiovascular Therapy and Prevention (Russian Federation), 2023, 22, 3870.	1.4	0
817	Booster vaccination against the SARS-CoV-2: mechanisms and efficiency. Cardiovascular Therapy and Prevention (Russian Federation), 2023, 22, 3820.	1.4	0
818	An overview of COVID-19 and current vaccine studies. DemiroÄŸlu Science University Florence Nightingale Journal of Medicine, 2021, 7, 57-65.	0.0	0
819	Application of Multivariate Data Analysis on Historical Recombinant Adenovirus Zoster Vaccine Production Data for Upstream Process Improvements. Journal of Pharmaceutical Sciences, 2024, 113, 1168-1176.	3.3	0
820	Clearance of persistent SARS-CoV-2 associates with increased neutralizing antibodies in advanced HIV disease post-ART initiation. Nature Communications, 2024, 15, .	12.8	0
821	Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans. Immunity, 2024, 57, 904-911.e4.	14.3	0
822	Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19. Vaccines, 2024, 12, 318.	4.4	0